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SUMMARY  
 
Atherosclerosis is an inflammatory disease characterized by the accumulation of 
cholesterol in the arterial intima and consequently the formation of atherosclerotic 
plaques. Formation of atherosclerotic plaques is initiated by the appearance of 
macrophage foam cell in the arterial intima. Foam cells are formed as excessive 
cholesterol accumulates in the cytosol of macrophages and finally the net influx 
exceeds the efflux of cholesterol. Under atherogenic conditions further chemically 
modified cholesterol accumulates in the macrophage foam cell finally leading to 
apoptosis. The dying foam cells contribute to the formation of the lipid core in 
atherosclerotic plaques. The efflux of cholesterol from macrophage foam cells is 
essential for preventing the progression of atherosclerosis. Active cholesterol efflux 
occurs through cholesterol transporters expressed on macrophages. The only 
unidirectional transporters, ABCA1 and ABCG1, transport intracellular cholesterol to 
distinct subpopulations of HDL. ApoA-I, the most important structural and functional 
component of nascent preβ-migrating HDL particles, receives cholesterol from ABCA1 
while ABCG1 transports cholesterol to mature α-HDL particles. Lipid-free HDL and 
apoA-I are sensitive to proteolytic modification leading to loss of function of these 
molecules. Many functional properties of apoA-I reside in its carboxyl-terminal domain. 
Functional apoA-I is essential for removal of cellular cholesterol and for cholesterol 
homeostasis. Cholesterol efflux initiates reverse cholesterol transport (RCT) which is 
the pathway for removal of cholesterol from the periphery for its final excretion into 
feces. The tiny fraction of total body-RCT that originates from the cholesterol-loaded 
macrophage foam cells located in the intima, is considered the only RCT component 
directly involved in atherosclerosis. 
Mast cells are bone marrow-derived inflammatory cells that migrate to their target 
tissues where they go through their final differentiation. Mast cells in different species 
and tissues express a varying degree of mast cell mediators. Mast cells infiltrate the 
inflamed arterial intima where they can be activated through several stimuli present in 
the atherosclerotic intima. Mast cell activation is immediately followed by 
degranulation, the release of the preformed mast cell mediators and the subsequent 
release of newly synthetized mediators within few hours of the mast cell activation. 
Mast cells release several inflammatory compounds of which histamine is probably the 
best known for its notorious effects in anaphylaxis. Mast cells also release other 
vasoactive compounds such as bradykinin and serotonin, at least as observed in rodent 
mast cells. In addition to these vasoactive compounds mast cells release upon 
activation their unique serine proteases, tryptase and chymase. Chymase involvement 
in the progression of atherosclerosis has been suggested in a number of studies. 
Chymase is an enzyme capable of degrading LDL components leading to increased 
uptake of the modified or granule-bound LDL by macrophage foam cells. Chymase is 
also able to proteolyze cholesterol acceptors such as lipid-free apoA-I and preβ-HDL 
resulting in diminished cholesterol efflux in vitro. Furthermore, treatment with 
chymase inhibitor has been shown to exhibit antiatherogenic properties. Chymase 
inhibition results in reduction of spontaneous atherosclerosis and reduces the size of 
the necrotic core in the atherosclerotic lesions in apoE-deficient mice.  
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The purpose of this study was to evaluate whether mast cell-dependent HDL and apoA-
I proteolysis would occur in vivo and whether such modification would alter the 
cholesterol efflux capacities of these cholesterol acceptors and finally affect the 
macrophage-specific RCT (mRCT).  In the present study it was demonstrated for the 
first time that mast cell activation in vivo resulted in HDL proteolysis. Systemic mast cell 
activation led to the degradation of apoAI, apoA-IV, and apoE present in HDL particles. 
Also the entire preβ-HDL and α-HDL subpopulations were reduced in mouse serum 
following systemic mast cell activation. Systemic activation of mast cells in mast cell-
competent mice, but not in mast cell-deficient mice, blunted the ability of serum and 
intraperitoneal fluid to promote cholesterol efflux from macrophage foam cells in vitro. 
Rat cardiac mast cell activation ex vivo led to the production of truncated apoA-I. 
Chymase cleaved lipid-free apoA-I at the carboxyl-terminal region at Phe229 and Tyr192 
or only at Tyr192 depending on the mast cell stimulus. Local peritoneal mast cell 
activation led to decreased ability of intraperitoneally injected apoA-I to promote 
macrophage cholesterol efflux in vitro. Furthermore treatment with intact lipid-free 
apoA-I but not chymase-treated apoA-I increased the overall mRCT from the peritoneal 
cavity to the intestinal contents within 3 hours. Importantly such an increase was fully 
blocked by the mast cell-specific degranulating compound 48/80 in mast cell-
competent mice but not in mast cell-deficient mice. Interestingly local mast cell 
activation in the skin was able to promote mRCT from skin to feces. This was due to 
increased vascular permeability and influx of plasma HDL particles to skin consequently 
leading to increased mRCT. This stimulatory effect could be reproduced by the sole 
administration of the mast cell mediators, histamine, serotonin, and bradykinin. 
Importantly histamine treatment in apoA-I deficient mice was unable to promote 
mRCT. Intra venous injection of HDL to apoA-I-deficient mice  was able to restore the 
histamine-dependent increase in mRCT. 
In conclusion, mast cell chymase is able to proteolyze HDL and lipid-free apoA-I 
reducing their abilities to promote cellular cholesterol efflux.. Proteolysis of lipid-free 
apoA-I by rat cardiac mast cell chymase can occur within minutes and results in the 
formation of carboxyl-terminally truncated apoA-I. ApoA-I proteolysis in vivo results in 
reduced mRCT. Local mast cell activation in the skin results in increased mRCT due to 
increased availability of cholesterol acceptors in the vicinity of macrophage foam cells. 
These two seemingly opposite results underline the pleiotropic role of mast cells in the 
development of atherosclerosis.    
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REVIEW OF THE LITERATURE 
 
 
1. Plasma Lipoproteins  
Plasma lipoprotein particles serve as transporters of lipids and cholesterol in the blood 
between the tissues of the body. Dietary or cholesterol newly synthesized by liver is 
transported by lipoproteins to peripheral tissues where cells use cholesterol as 
building-blocks to create cell membranes, steroid hormones and other essential 
cholesterol-based molecules. Lipoproteins comprise spherical and discoidal 
macromolecular particles composed of lipids and specific proteins, the apolipoproteins 
(apo). Plasma lipoprotein particles include, in the order of increasing protein densities 
and decrease in size, chylomicrons, very-low-density lipoproteins (VLDL), intermediate-
density lipoproteins (IDL), low-density lipoproteins (LDL), and high-density lipoproteins 
(HDL). The relative sizes and densities are portrayed in Figure 1. Lipoproteins serve as 
the main cholesterol transporters in the body. Since cholesterol is virtually insoluble in 
blood it needs a water soluble carrier for transportation. Generally speaking plasma 
LDL are particles transporting cholesterol to tissues and HDL from periphery back to 
liver for final excretion out of the body. High LDL-cholesterol and low HDL-cholesterol 
levels are known contributors to the risk of cardiovascular diseases (CVD), the cause of 
47% of all deaths in Europe (Nichols et al. 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Approximate sizes and densities of serum lipoprotein 
Lipoproteins interchange lipids, cholesterol and lipoproteins making all lipoproteins subclasses 
dynamically changing and heterogeneous groups of molecules. The spheres portrayed in this picture 
show the relative sizes of the particles compared to each other but in vivo a wide range of sizes and 
densities are present. The hydrophilic surface layer is represented in blue and the hydrophobic core in 
orange. The more intensely colored core represents the cholesterol and cholesteryl esters and the 
lightly colored surroundings triglycerides. The width of the rings represents the approximate amount 
of each component. Data derived from Champe et al., 2005, Hames and Hooper, 2011. 
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1.1. Composition of plasma lipoproteins 
All lipoprotein particles share a common structure as spherical, micellar complexes 
with an amphipathic surface monolayer and a hydrophobic lipid core (Kumar et al. 
2011). The general structure is portrayed in Figure 2. The neutral lipid core serves as 
transportation module for esterified cholesterol and triglycerides (TGs). The core is 
surrounded by a shell consisting of apolipoproteins, phospholipids and non-esterified 
cholesterol (Champe et al. 2005). These amphiphilic molecules are oriented in such a 
manner that their hydrophilic portions are faced outwards to the aqueous plasma 
compartment making the molecule water-soluble. The esterified cholesterol and TGs 
transported by plasma lipoproteins are either of diet origin or de novo synthesized by 
liver and intestine.  
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic drawing of lipoprotein structure. Information derived from Champe et al.  
2005.  
 
1.2. Metabolism of apoB-containing lipoproteins 
The proatherogenic lipoproteins are called apoB-containing lipoproteins including 
chylomicrons, VLDL, IDL and LDL and they each contain an apoB molecule at the 
particle surface. ApoB-containing lipoprotein metabolism can be divided into 
exogenous and endogenous pathways that transport lipids of either dietary or hepatic 
origin, respectively, for the use of peripheral tissues. Both pathways begin with the 
secretion of triglyceride-rich lipoproteins either from intestinal mucosal cells as is the 
case with chylomicrons in the exogenous system or from hepatic cells as is the case 
with VLDL in the endogenous system. The single copy of apoB  remains with the 
particle throughout its interconversions in the plasma.  (Brown et al. 1981). In the 
intestinal mucosal cells ApoB-48, unique to chylomicrons, as well as lipids are 
assembled to chylomicrons where they are packaged into secretory vesicles (Champe 
et al. 2005). Chylomicrons in the secretory vesicles fuse with the plasma membrane 
and are released to blood circulation via lymphatic circulation. Once in circulation the 
nascent chylomicrons are rapidly modified to functional chylomicrons by receiving apoE 
and apoC-II from HDL. Other apolipoproteins associated with chylomicrons include 
apoAI, II, IV and apoC-I and III.  (Nakajima et al. 2011). Chylomicrons are transported in 
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the blood stream to peripheral target tissues where they are metabolized by 
lipoprotein lipase (LPL) present on the capillary endothelium activated by apoC-II. As 
the chylomicrons circulate the hydrolytic activity of LPL reduces their triglyceride 
content by 75-90% and additional removal of apoC lipoproteins back to HDL produces 
chylomicron-remnants that are taken up by B-100-E receptors on hepatocytes (Champe 
et al. 2005). Within the liver, the chylomicron remnant is decomposed to its amino 
acids and component lipids. Cholesterol released from lysosomes in hepatocytes can be 
excreted into bile, converted into bile acids, incorporated into VLDL for secretion into 
the blood via the Golgi apparatus or esterified with long-chain fatty acids and stored in 
the hepatocyte. (Olson 1998). VLDL is produced in the liver. These lipoprotein particles 
are composed mainly of TGs but they also carry phospholipids and cholesterol. VLDL-
particles are secreted directly into the blood by the liver as nascent VLDL particles 
containing apoB-100. As with the chylomicrons, VLDL obtain apoE and apoC-II from 
circulating HDL the latter required for the activation of LPL. VLDL may also be 
associated with apoC-I and III. (Champe et al. 2005, Nakajima et al. 2011). VLDL pass 
through the circulation and provide peripheral tissues, mainly muscles and adipose 
tissue, with TGs.  The depletion of TGs is mediated by LPL and the released free fatty 
acids (FFAs) are taken up by tissues. The VLDL remnants remain in the blood, first as 
IDLs and then as LDLs. ApoC and apoE are removed from IDL back to HDL and the only 
apolipoprotein remaining in the LDL-particle is the apoB-100. LDL contain much less 
triylglycerides than VLDL and have a high concentration of cholesterol and cholesteryl 
esters  (Hames and Hooper 2011). 
1.2.1. Regulated receptor mediated endocytosis of LDL 
The physiological function of LDL is to provide cholesterol to peripheral tissues. LDL is 
taken up by target cells in peripheral tissues through receptor-mediated endocytosis as 
shown in Figure 3. The LDL-receptor (LDLR), a transmembrane glycoprotein on the 
surface of the target cells, specifically binds apoB-100 in the LDL coat and internalizes 
LDL, ultimately merging with a lysosome. (Hames and Hooper 2011). In the lysosome, 
both the apolipoprotein and lipids of LDL are degraded to monomers and released into 
the cytoplasm. LDL-derived cholesterol acts at the cellular level as a negative feedback 
mechanism and prevents further accumulation of cholesterol into the cell.  Through 
this regulatory mechanism, cells keep the level of unesterified cholesterol in 
membranes remarkably constant despite wide fluctuations in cholesterol requirements 
and exogenous supply (Goldstein and Brown 2009). 
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Figure 3. Cellular uptake and degradation of LDL 
LDL-receptors (LDLR) reside on coated pits on the cell surface and bind specifically the apoB-100 on 
the surface of LDL-particle. LDLR complex is then internalized by endocytosis. The forming vacuole 
loses its clathrin coat and fuses to form endosome. LDL is then separated from LDLR by endosomal 
ATPase leaving the receptors free to migrate back to the cell surface for recycling of the receptors 
while the LDL stays in the vesicle. Lipoprotein remnants are transferred from vesicles to lysosomes 
where they are degraded by lysosomal enzymes releasing free cholesterol, amino acids, fatty acids 
and phospholipids. Free cholesterol acts as a negative feedback mechanism on 3-hydroxy-3-
methylglutaryl coenzyme A reductase (HMG-CoA reductase) which is needed for the de novo 
production of cholesterol and on LDLR gene expression.  Some cholesterol may be used as cell 
structural components such cell membrane components and the rest is esterified by acyl 
CoA:cholesterol acyltransferase (ACAT) to be stored as cholesteryl esters. Free cholesterol may also 
be used for the production of bile acids (BAs) as in the liver or for steroid hormone synthesis, 
depending on the cell type. LDL, low density lipoprotein. Data derived from (Olson 1998) and 
references mentioned in the text.  
 
1.2.2. Scavenger receptor mediated endocytosis of LDL 
The LDLR mediated uptake of LDL-cholesterol is not the only means of transport for 
intracellular cholesterol. In the late 1970s’ Goldstein and Brown observed a highly 
efficient uptake of chemically modified LDL by mouse peritoneal macrophages  
(Goldstein et al. 1979). These cells expressed binding sites of high affinity for acetylated 
LDL and also for maleylated LDL but not for native LDL. Similar binding site was found 
on rat peritoneal macrophages, guinea pig Kupffer cells, and cultured human 
monocytes but not on human lymphocytes or fibroblasts, mouse L cells or Y-1 adrenal 
cells, or Chinese hamster ovary cells. (Goldstein et al. 1979). This rapid and efficient 
uptake of chemically modified LDL is mediated through scavenger receptors (SR). SRs 
comprise a structurally diverse group of proteins including eight different classes of 
membrane and soluble proteins (Class A, B, C, D, E, F, G, and H) encoded by distinct and 
unrelated genes (Stephen et al. 2010). Scavenger receptor classes are grouped 
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according to their structural similarities but there is great structural diversity between 
the different classes. SRs are expressed by myeloid cells, selected endothelial cells and 
some epithelial cells and recognize many different ligands, including microbial 
pathogens as well as endogenous and modified host-derived molecules including 
modified lipoproteins (Pluddemann et al. 2007).  
The receptors mainly responsible for the binding and internalizing of chemically 
modified LDL are SR class A (SR-A) and a class B receptor CD36 expressed on 
macrophages (Podrez et al. 2000, Stephen et al. 2010). Most common forms of LDL 
modification are oxidation and acetylation but also mast cell-derived chymase is able to 
degrade apoB-100 on LDL-particles resulting in destabilization and fusion of LDL 
particles (Kovanen 2004, Champe et al. 2005). Such chemically modified LDL loses its 
affinity to LDLRs but gains affinity for SRs. Unlike the highly regulated LDLR pathway, 
the SR is not down-regulated in response to increasing intracellular levels of 
cholesterol. In contrast exposure to lipoproteins results in a marked induction of 
macrophage SR messenger-RNA (mRNA) expression. Importantly the presence of 
cholesterol acceptor particles in culture medium results in a decrease in macrophage 
SR mRNA expression, which is in relation to the cholesterol loss from the cells.  (Han 
and Nicholson 1998).  Thus modified LDL acts as positive feedback on SR expression on 
macrophages and enables the mass deposition of cholesterol in macrophages. In stable 
macrophages, cholesterol efflux mechanisms balance cholesterol influx mechanisms 
and accumulating lipids do not overwhelm the cell (Reiss and Cronstein 2012). Under 
atherogenic conditions macrophages infiltrate the intima of the arterial wall. Thus 
begins the formation of an atherosclerotic plaque as the number of macrophages 
increase and are filled with lipid droplets. (Stary et al. 1994). The presence of these 
histologically visible foam cells is the initial step of atherosclerosis (Kovanen 2004). The 
first grossly visible lesion is the fatty streak lesion characterized by layers of 
macrophage foam cells, lipid droplets within intimal smooth muscle cells, minimal 
coarse-grained particles and heterogeneous droplets of extracellular lipid. When the 
lesions progress the intima thickens and more and more cholesterol accumulates 
within the cells and further pools of extracellular lipid characterize these lesions. (Stary 
et al. 1994).  Once the foam cells are filled with lipid droplets they finally perish by 
apoptosis and this may play a role in the formation and enlargement of the lipid core 
(Hegyi et al. 1996).  
 
1.3. High-density lipoprotein metabolism 
High-density lipoprotein (HDL) particles are the smallest and densest of the plasma 
lipoproteins. The physiological function of HDL is the opposite to that of LDL.  Rather 
than transporting cholesterol to tissues it removes cholesterol from the peripheral 
tissues. In epidemiological studies high plasma HDL-cholesterol concentration has been 
shown to be cardioprotective. In addition, in a wide variety of studies low plasma HDL 
levels have been associated with an increased risk for CVD and a low HDL-cholesterol 
level is the most common lipoprotein abnormality among patients with coronary artery 
diseases  (Ding et al. 2014, Khalili et al. 2014). Low plasma HDL-cholesterol is also 
associated with the metabolic syndrome, a cluster of factors including low HDL-
cholesterol, elevated triglycerides, insulin resistance, abdominal obesity, and elevated 
blood pressure all of which are associated with an increased risk of CVD.  (Weissglas-
Volkov and Pajukanta 2010). HDL particles exhibit multiple antiatherogenic effects. The 
best known of these effects is the ability of HDL to promote the removal of cholesterol 
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from macrophage foam cells  (Lee-Rueckert and Kovanen 2011). HDL also inhibit LDL 
oxidation, promote endothelial repair, improve endothelial function, have anti-
thrombotic and anti-inflammatory properties,  decrease white adipose tissue mass, 
increase energy expenditure, and inhibit the binding of monocytes to the endothelium 
(Cockerill et al. 1995, Morgantini et al. 2011, Mineo and Shaul 2012, Gordts et al. 2014). 
HDL has also been shown to reduce experimentally induced atherosclerotic lesions in 
animal models  (Badimon et al. 1990, Chiesa et al. 2002, Ibanez et al. 2008). 
1.3.1. Formation of nascent HDL 
HDL particles are secreted into circulation by the liver and intestine or dissociate from 
chylomicrons and VLDL during LPL mediated hydrolysis of triglycerides (von Eckardstein 
et al. 2005). The formation of HDL depends on the initial lipidation of lipid-poor or lipid-
free apoA-I and its interaction with the ATP-binding cassette transporter (ABC) A1 
(Duong et al. 2006). This leads to the efflux of phospholipids and unesterified 
cholesterol from many cells including hepatocytes and macrophages, and to the 
formation of discoidal HDL precursors (von Eckardstein et al. 2005). These discoidal 
HDL particles are small in size and have differences in the free (unesterified) cholesterol 
contents and phospholipid composition  (Duong et al. 2006). The nascent discoidal HDL 
particles are called collectively preβ-HDL according to their characteristic feature to 
migrate with preβ-mobility in agarose electrophoresis gel (Lee-Rueckert and Kovanen 
2006). The major structural protein component of HDL is apoA-I, a polypeptide, 
produced in the liver and intestine with a primary structure of 243 amino acids and a 
molecular weight of 28 kDa  (Brewer et al. 1978, Thomas et al. 2008). The primary 
structure of apoA-I has been described in humans and other species including rats and 
mice and a considerable degree of homology is observed between the species. There is 
also cross-reactivity to monoclonal antibodies against apoA-I between the apoA-I of 
different species indicating high structural similarity.  (Collet et al. 1997). ApoA-I 
molecule has a partially folded native-like secondary structure “molten globular” with a 
tertiary structure that is less organized. In the molten globular state the α-helices 
remain intact with β-sheets and the α-helices form the primary secondary structure 
within lipid-free apoA-I. These helices make up the main structural and functional parts 
on apoA-I. The area between the hydrophobic and hydrophilic ends of the helix is 
enriched with positively charged amino acids, but the function of these amino acids is 
not known. Lipid-free apoA-I consists of two distinct unfolding domains, the N-terminus 
(1-187) and C-terminus (88-243), the N-terminus being somewhat more compact and 
organized in structure. (Thomas et al. 2008). 
Most plasma apoA-I circulates in lipoproteins and is associated with mature HDL 
particles (>90%), yet ~5% forms monomeric lipid-poor or lipid-free species. The latter 
represents the  metabolically active species and is a primary cholesterol acceptor and is 
central to HDL biogenesis  (Lee-Rueckert and Kovanen 2006, Jayaraman et al. 2012). 
Preβ-HDL plays a pivotal role in lipoprotein metabolism by facilitating the ABCA1-
mediated efflux of excess cholesterol from macrophages and other peripheral cells. 
 
1.3.2. Lipidation of HDL 
A second lipidation step essential for plasma preβ-HDL maturation is the activation of 
the LCAT enzyme by lipid bound apoA-I.  Activity of this enzyme results in the synthesis 
of cholesterol esters from the free cholesterol taken up by preβ-HDL providing a 
hydrophobic core and transforming the discoidal lipid-poor particle to spherical lipid-
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rich α-HDL  (Thomas et al. 2008, Brewer 2011).  Inactivation of either of ABCA1 or LCAT 
results in low plasma HDL-cholesterol levels  (Thomas et al. 2008). The biggest HDL 
particles have diameters of 9-12 nm and contain several apoA-I molecules besides 
other amphipathic apolipoproteins. The second major apolipoprotein of HDL is apoA-II, 
a protein with molecular weight of 18 kDa and a similar secondary structure to apo A-I, 
with seven amphipathic helices. These amphipathic helices may play an important role 
in the binding of apo A-II to lipoprotein particles (Brewer et al. 1978, Brewer 2011). 
ApoA-II is mainly associated with HDL-particles but a small fraction is also found with 
chylomicrons and VLDL  (Blanco-Vaca et al. 2001). Apart from apoA-I and apoA-II other 
minor apolipoproteins including apoA-IV, apoE, apoC-I, apoC-II and apoC-II are 
associated to HDL, but only apoA-I and -II are responsible for exerting the biological 
actions such as receptor binding and the activation of enzymes (von Eckardstein et al. 
2005, Brewer 2011). ApoA-II plays a complex role in lipoprotein metabolism, with some 
antiatherogenic properties such as the maintenance of a stable HDL pool, and other 
proatherogenic properties such as decreasing clearance of atherogenic lipoprotein 
remnants and promotion of insulin resistance. (Weng and Breslow 1996). The newly 
formed mature HDL-particles are further divided to HDL3 and HDL2 according to their 
size and density. HDL3 are smaller and converted to the larger HDL2 by the acquisition 
of lipids and apolipoproteins released during the stepwise delipidation and remodeling 
of the TG-rich chylomicrons and VLDL, and by the esterification of the cholesterol 
removed from peripheral tissues  (Brewer 2011). The structure and size of a particular 
spherical HDL particle in circulation probably changes many times during its circulatory 
period (typically 2-3 days) but there appear to be minimal changes in the conformation 
of apoA-I in the larger and smaller spherical HDL particles  (Fielding and Fielding 1995).  
1.3.3. Reverse cholesterol transport 
Reverse cholesterol transport (RCT) is the pathway comprising several different steps 
between cholesterol efflux from macrophage foam cells and the final excretion of 
cholesterol into the feces either as neutral sterols or after its metabolic conversion into 
bile acids as portrayed in Figure 4. This is a selective, irreversible transportation system 
of cholesterol from peripheral tissues to final disposal and an essential component of 
cholesterol homeostasis (Champe et al. 2005). HDL reaches the interstitium, to the 
proximity of cholesterol foam cells, by passing through vascular endothelium. HDL 
moves from plasma across the endothelium to the interstitial fluid by transcytosis. The 
flux of HDL to interstitial fluid is linearly related to its concentration in plasma and 
there is a steady state of HDL between interstitial fluid and plasma compartment with 
circadian fluctuations (Hovorka et al. 2006).  Interstitial fluid travels down a pressure 
gradient from blood to lymphatic capillaries such that the composition of lymph is a 
close reflection of extravascular interstitial fluid (Randolph and Miller 2014). Before the 
cytoplasmic cholesterol can be effluxed to extracellular acceptors, it must be 
hydrolyzed as free cholesterol  (Wang and Rader 2007).  
The initial step in macrophage specific RCT (mRCT) is the receptor mediated efflux of 
free cholesterol from macrophage foam cells via ABCA1 to lipid-poor apoA-I or preβ-
HDL. This pathway depends on a distinct domain within the C-terminus of apoA-I, and 
results in the formation of HDL precursors that subsequently mature to HDL as 
described above  (von Eckardstein et al. 2005). Overexpression of apoA-I in mice has a 
protective role against atherosclerosis due to acceleration in mRCT (Escola-Gil et al. 
2009). Studies on both natural and engineered mutations in the human apoA-I 
molecule have revealed that the C-terminal region is important for lipid binding and 
that the central region corresponding to residues 121–186 is important for activation of 
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LCAT  (Lund-Katz and Phillips 2010). ApoA-I and preβ-HDL are susceptible to proteolytic 
modification which impairs their ability to promote cholesterol efflux from macrophage 
foam cells  (Lee-Rueckert and Kovanen 2011).  Similarly, serum containing apoA-I 
Milano, a naturally occurring mutated variant of the apoA-I protein found in human 
HDL, increases the rate of cholesterol efflux from macrophage foam cells in vitro 
compared to normal serum. This effect is abolished when the lipoprotein is subjected 
to proteolytic modification (Favari et al. 2007). A similar decrease in efflux promoting 
ability was seen when discoidal reconstituted HDL (rHDL) particles were subjected to 
proteolytic degradation in vitro. Pretreatment of rHDL with chymase, capable of 
cleaving apoA-I, for 2 hours resulted in 20% reduction in the cholesterol efflux rate in 
vitro compared to non-treated rHDL.  (Lee et al. 2003).  Thus not only the quantity but 
also the quality of apoA-I or HDL can have effect on the ABCA1 mediated cholesterol 
efflux. Indeed, in a recent population-based cohort study serum HDL cholesterol efflux 
capacity was inversely associated with the incidence of cardiovascular events, while 
mere baseline HDL level was not alone associated with cardiovascular events  (Rohatgi 
et al. 2014). This suggests that high HDL level, as such might not alone be 
cardioprotective, unless the HDL is functional and has a high cholesterol efflux capacity.  
Drugs have been tested to increase plasma HDL levels but the benefits so far have not 
been convincing. Niacin is a potential drug that has been tested on human subjects to 
increase plasma HDL levels. In a clinical study patients were treated with either niacin 
and statin or statin alone and despite the ability of niacin to increase plasma HDL levels 
by 10% this beneficial change in serum lipoproteins did not reduce CVD risk events 
compared to statin therapy alone. Niacin has also many side effects, including 
hepatotoxicity, hyperglycemia, and flushing.  (Hafiane and Genest 2013). Recently it 
was shown, however, that in a primate model a short-term low dose niacin treatment 
was sufficient to markedly increase serum HDL and apoA-I levels and to decrease 
plasma LDL levels without any side-effects (Chauke et al. 2014). In vivo, preβ-HDL in 
plasma is converted to α-HDL for the delivery of cholesteryl esters to hepatic cells while 
in the intestinal fluid α-HDL is remodelled to preβ-HDL readily available to pick up 
unesterified cholesterol from peripheral cells (Miller et al. 2013). It is of note, that 
when the total volume of interstitial fluid is taken into account and its concentration 
therein considered, approximately half of all apoA-I in the body is extravascular and 
found within interstitial fluid of peripheral organs possibly making intestinal fluid a 
major site of whole body pre-β-HDL production in vivo (Miller et al. 2013, Randolph and 
Miller 2014).  Given this, not only plasma but also interstitial fluid and lymph should be 
considered as a target to increase HDL levels for the removal of cholesterol from 
cholesterol foam cells. 
The intactness of ABCA1 is also essential for the cholesterol transportation from foam 
cells to lipid-poor lipoproteins. In Tangier disease a genetic defect results in a structural 
mutation in the ABCA1 transporter. This defect leads to decreased efflux of cholesterol 
from the peripheral cells and to reduced lipidation of apoA-I. The poorly lipidated HDL 
is rapidly degraded by the kidney, leading to low plasma HDL levels that are 
characteristic of Tangier disease. (Thomas et al. 2008). Furthermore, transplantation of 
bone marrow from ABCA1 knockout mice to LDLR knock-out mice increases the 
development of atherosclerotic lesions while transplantation of bone marrow from of 
ABCA1 overexpressing mice inhibits progression of atherosclerotic lesions (van Eck et 
al. 2002, Van Eck et al. 2006).  
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Other active transporters of free cholesterol from macrophages to HDL are ABCG1 and 
ABCG4. ABCG1 and ABCG4 stimulate cholesterol efflux to both smaller (HDL-3) and 
larger (HDL-2) subclasses but not to lipid-poor apoA-I (Wang et al. 2004).  Additional 
efflux capacity might be provided by scavenger receptor class B type 1 (SR-BI) or by 
aqueous diffusion to the larger HDL subclasses  (Rothblat and Phillips 2010, Annema 
and Tietge 2012). The expression of SR-BI in macrophages enhances HDL-mediated 
cholesterol efflux. This is in contrast to the effect of SR-BI in liver or steroidogenic cells, 
in which SR-BI mediates the influx of cholesterol (von Eckardstein et al. 2005).  
Once the free cholesterol is effluxed to HDL in the extravascular compartment, HDL 
from interstitial fluid is taken up by lymph. Lymphatic capillaries are composed of a 
single layer of endothelial cells bound together by button-like junctions creating flaps, 
which allow receptor-independent entry of molecules, such as HDL into lymph 
(Randolph and Miller 2014). Lymphatic capillary endothelial cells express SR-BI and 
impairment on the function of these receptors result in decreased accumulation of 
cholesterol to lymph derived from cholesterol foam cells resulting in net reduction of 
RCT. This suggests that entry of interstitial HDL through lymphatic vessels depends on 
SR-BI and probably outweighs passive entry  (Lim et al. 2013). Lymphatic fluid is 
transported to progressively larger lymphatic vessels culminating in the right lymphatic 
duct and the thoracic duct. Both ducts drain to subclavian veins and HDL enters 
circulation. In plasma compartment HDL is esterified by LCAT clearing space on the HDL 
surface for the uptake of additional free cholesterol  (Annema and Tietge 2012). 
Cholesterol in HDL particles is then transported in the plasma compartment to liver. 
Hepatic cells express SR-BI receptors which mediate the selective uptake of HDL. SR-BI 
functions to remove free cholesterol and cholesterol esters selectively from 
lipoproteins without lipoprotein particle uptake and degradation resulting in the 
excretion of cholesterol to bile, either as free cholesterol or as bile acids (Brewer 2011, 
Annema and Tietge 2012). Overexpression of hepatic SR-BI in mice leads to reduced 
foam cell-derived cholesterol concentration in plasma and increased passing of 
cholesterol to feces while SR-BI deficiency causes an increased foam cell-derived 
cholesterol concentration in plasma and reduced passing of cholesterol to feces in a 48 
hour macrophage-RCT assay  (Zhang et al. 2005). Cholesteryl ester transfer protein 
(CETP) promotes the transfer of cholesteryl esters from HDL to apoB-containing 
lipoproteins, including VLDL, IDL, and LDL  (Barter et al. 2003). In this way also hepatic 
receptors for apoB containing lipoproteins might participate in RCT  (Annema and 
Tietge 2012). The role of this pathway is however unclear. In rabbits inhibition of CETP 
leads to reduced atherosclerosis while in apoE knockout mice CETP inhibition inflicts 
increased atherosclerosis (Barter et al. 2003, Wang and Rader 2007). In humans 
increased alcohol consumption results in decreased plasma CETP concentration while 
the specific activity of the protein remains unchanged or even increased. Such patients 
have increased plasma HDL levels. (Hannuksela et al. 1992). Of note, inhibition of CETP 
does not lead to reduction in the progression of atherosclerosis despite of the 
increased plasma HDL and decreased LDL concentrations  (Kastelein et al. 2007).  
After secretion of cholesterol to the bile it is temporarily stored in gall bladder from 
where it is discharged to small intestine postprandially. Finally, within the intestinal 
lumen altered absorption rates of cholesterol can then further impact on the amount 
of foam cell-derived cholesterol that is finally excreted from the body  (Lee-Rueckert et 
al. 2013). 
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Figure 4. Reverse cholesterol transport 
Low density lipoprotein (LDL) is taken up by macrophage foam cells by scavenger receptors (SR) eg. 
SR-A or CD36. Cholesterol is stored as cholesteryl esters (CE) and the reverse cholesterol transport 
(RCT) is initiated by the efflux of newly hydrolyzed free cholesterol (FC) by ATP-binding cassette 
transporter ABCA1 to lipid-poor apolipoproteinA-I (apoA-I or to nascent discoidal preβ high density 
lipoprotein (HDL). Additionally FC can be released from the cells via ABCG1 or SR-B1 to mature α-HDL. 
FC is esterified in preβ-HDL by lecithin cholesterol acyl transferase (LCAT) forming mature α-HDL. 
Cholesteryl ester transfer protein (CETP) promotes the transfer of CEs from HDL to apoB-containing 
lipoproteins, including VLDL and LDL. This way hepatic LDL receptors (LDLR) may participate in RCT. 
SR-BI in hepatic cells is responsible for the uptake of HDL and they remove FC and CEs for exertion of 
cholesterol to bile, either as FC or as bile acids (BA). Data derived from references mentioned in the 
text. 
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2. Mast Cells 
Mast cells were first accurately described by Paul Ehrlich in 1878 in his doctoral thesis 
Beiträge zur Theorie und Praxis der histologischen Färbung. Ehrlich was able to visualize 
the protoplasmic granules of these cells by an alkaline stain. He considered these cell 
granules to be nourishment for the cells and thus named the cells mast cells or 
“mastzellen”, referring to the German word “Mästung”, meaning overfeed. Mast cells 
are heterogeneous, large, ovoid cells (20-30 µm) with a spherical nucleus and 
cytoplasm filled with large intensely basophilic granules (Figure 5). Mast cells are 
inflammatory cells that are best known for their harmful effects in severe allergic 
reactions. Mast cells derive from hematopoietic stem cells and they migrate as 
immature progenitors into connective or mucous tissues where they differentiate to 
mature mast cell phenotypes  (Galli and Tsai 2010).  In vertebrates, mast cells are found 
in almost all vascularized tissues, particularly at the interfaces of the body such as the 
skin, the airways, and the gastrointestinal tract  (Kitamura 1989).  The localization of 
mast cells enables them to be one of the first cells to interact with any possible foreign 
material forcing its way through the defensive barriers of the body. Apart from their 
role in allergy and innate immunity, mast cells are associated with chronic 
inflammatory diseases such as atherosclerosis, rheumatoid arthritis, multiple sclerosis 
and diabetes mellitus as well as with cancer and obesity  (Anand et al. 2012). 
   
 
 
 
 
 
 
 
 
 
 
Figure 5. Mast cell 
Light microscopy of intact rat cardiac mast cells stained with toluidine blue (0,1%), 40x magnification. 
Picture taken by Ilona Kareinen (30.06.2010).  
  
40µm 
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2.1. Origin, development, and migration to tissues 
Mature mast cells are only found in tissues and they are undetectable in bone marrow 
and peripheral blood. Originally it was believed that mast cells were developed from 
certain types of connective tissue cells or that lymphoid cells were involved. In the 
1970s mast cell precursors were first detected in mouse  bone marrow and peripheral 
blood and in the liver of mouse embryos  (Kitamura et al. 1977, Kitamura et al. 1979, 
Kitamura et al. 1979, Kitamura 1989). Identification of the mast cell progenitor finally 
established that developmentally mast cells belonged to the hematopoietic lineage  
(Rodewald et al. 1996). 
Mast cells, unlike most other hematopoietic cells, are released into the circulation from 
the bone marrow as immature, committed mast cell progenitors (MCp)  (Rottem et al. 
1991). In the bone marrow, hematopoietic stem cells develop into MCp through a 
stepwise maturation presented in Figure 6. Committed MCp are a heterogeneous cell 
population but they have been characterized in the mouse to express CD34, c-kit, and 
CD13 but not high affinity IgE receptor (FcεRI)  (Jamur et al. 2005). In humans, mast 
cells arise from a common mast cell committed progenitor expressing CD34 (Maaninka 
et al. 2013).  
Migration of the MCp is regulated by many chemotactic factors and molecules and is 
dependent on the specific integrins, transmembrane receptors, expressed on the 
surface of MCp. The interplay between the integrins and their ligands in different 
tissues determines the final target tissue of the MCp and is represented in detail in 
Figure 6. Finally the microenvironment of the tissue into which the mast cells have 
migrated defines the proliferation, survival, and the phenotype of the mature mast cell. 
These phenotypic features include the susceptibility to, ability to store and/or produce 
various secreted products, and the magnitude and the nature of the secretory 
responses to specific stimuli of activation (Galli and Tsai 2010). The most important 
factor for mast cell survival and development is the stem cell factor (SCF). The 
importance of SCF for the mast cell maturation is reflected by the fact that the SCF 
receptor c-kit is expressed on the surface of mast cells in every step of the mast cell 
maturation (Galli et al. 1993). In the peripheral target tissues the committed MCp 
continue their differentiation and proliferation in the presence local growth factors, 
such as IL-3, IL-4, IL-9, IL-10, and nerve growth factor (NGF) and all of them can 
influence the phenotype of the mature mast cell  (Metcalfe et al. 1997).  
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Figure 6. Mast cell development from hematopoietic stem cells to mature mast cells 
Mast cells develop into mast cell progenitors (MCp) from hematopoietic stem cells (HSC) via 
multipotent progenitors (MPP), common myeloid progenitors (CMP) and granulocyte/monocyte 
progenitors (GMP) in the bone marrow (BM). Homing of MCp from the circulation depends on the 
integrins expressed on MCp and their ligands in the tissues. Vascular cell adhesion molecule-1 (VCAM-
1) enables α4β1-and α4β7-integrin-expressing MCp to enter and adhere to lung tissue. Chemokine 
receptors CXCR2 and CCR2 and their ligands chemokines CXCL2 and CCL2 are also involved in the 
homing of MCp and MCp number in the lung is regulated by CD4+T and CD11c+cells. In the gut VCAM-
1 and mucosal vascular addressin cell adhesion molecule 1 (MAdCAM-1) interaction with  α4β1 and 
chemokine receptor CXCR2 and its ligand CXCL2 are required for homing of MCp. Leukotriene B4, 
prostaglandin E2 and chemokine CCL2 attract BLT1-R, EP3-R and CCR2 expressing MCp to the skin. 
Immunoglobulin E (IgE) alone and phosphoinositide 3-γ kinase (PI3Kγ) and tumor necrosis factor-α 
(TNF-α) released from activated mast cells are involved in homing of MCp in IgE-chanllenged skin. 
Integrins αMβ2 and αIIbβ3 on are required for homing of MCp to the peritoneal cavity. In the 
peripheral tissues stem cell factor (SCF) regulates mast cell development. Local growth factors, such 
as IL-3, IL-4, IL-9, IL-10 and nerve growth factor (NGF) influence the phenotype of the maturing mast 
cell. Data derived from (Gurish et al. 2001, Abonia et al. 2005, Abonia et al. 2006, Collmann et al. 
2013, Dahlin and Hallgren 2014) and references mentioned in the text.  
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2.2. Heterogeneity   
Since mast cell development into mature cell populations is completed in the 
peripheral tissues they exhibit marked heterogeneity. Histochemical and functional 
heterogeneity of mast cells was first introduced by Enerbäck in the 1960s based on his 
studies on rat mast cells. Mast cells were divided into two major phenotypes, mucosal 
mast cells (MMC), found in intestinal lamina propria and connective tissue mast cells 
(CTMC) found mainly in peritoneal cavity and skin, based on their staining properties by 
a safranin stain (Enerback 1966). The staining properties of these two groups of mast 
cells differ since CTMCs contain large amounts of heparin in their granules which stain 
red with safranin. The division of mast cells into CTMCs and MMCs is still valid for 
rodent mast cells and the mast cells in these groups differ in morphological and 
histological properties, as well as in biochemical properties  and function  (Metcalfe et 
al. 1997). MMCs are smaller, more variable in shape, and as a rule contain fewer 
granules of a more variable size and shape than CTMCs  (Kitamura 1989). In addition to 
the differences between the MMCs and CTMCs there is also a marked heterogeneity 
between mast cell populations even in same body compartment. In the rat, the mast 
population in the peritoneal cavity goes through cyclic, dynamic changes and cells in 
each phase of the cycle can be observed at different stages of embryonic development 
and at different ages  (Combs et al. 1965).  
Based on histological staining, human mast cells are traditionally divided in two groups 
based on their protease content of the granules  (Beghdadi et al. 2011), namely 
tryptase and chymase positive mast cells (MCTC) and tryptase positive mast cells (MCT),.  
This division, however, is based on early studies on mast cells and might be outdated. 
Recently, it was discovered that in humans all mast cells arise from common circulating 
mast cell progenitors and in the presence of SCF all mast cells have the potential of 
expressing the entire variety of mast cell proteases including not only tryptase and 
chymase, but also carboxypeptidase A3, cathepsin G, and granzyme B (Maaninka et al. 
2013).  Here the comparison between human and rodent mast cells is portrayed by the 
traditional division. 
MCTC are mainly found in the skin and small intestinal submucosa whereas MCT are 
found in the alveolar septa of the lung and small intestinal mucosa (Metcalfe et al. 
1997).  Therefore, in terms of tissue localization, the rodent MMC corresponds most 
closely to the human MCT, whereas the rodent CTMC corresponds most closely to the 
MCTC. The structural heterogeneity also translates into functional heterogeneity. In 
rodents a mast cell specific degranulating compound 48/80 (C48/80) induces histamine 
release from rat CTMC but fails to induce release from rat MMC. Similarly, C48/80 
activates mouse CTMC but does not activate mouse bone marrow-derived cultured 
mast cells. Functional heterogeneity is also found between MCTC and MCT. MCTC 
purified from the skin release histamine in response to C48/80, morphine, and 
substance P, but MCT from the lung and intestinal mucosa do not  (Kitamura 1989). 
These differences in functional properties are a result of differences in mast cell 
receptors and receptor affinities.  
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2.3. Activation 
Depending on their location, stage of maturation or species, mast cells express 
different types and levels of surface antigens and receptors, some of which are 
involved in activation and others in cell recognition  (Theoharides et al. 2012). 
Degranulation and the exocytosis of the intracellular granules are considered the 
hallmark of mast cell activation (Figure 7). The wide variety of surface receptors and 
their agonists is needed for an efficient and tissue-specific mast cell function.  
 
 
 
 
 
 
 
 
 
Figure 7. Degranulated mast cells 
Light microscopy of a degranulated rat cardiac mast cells activated with compound 48/80 and stained 
with toluidine blue (0,1%), 40x magnification. Picture taken by Ilona Kareinen (30.06.2010) 
 
The most comprehensively studied activation route of mast cells is the interaction 
between a multivalent antigen with its specific immunoglobulin E (IgE) antibody and 
the high-affinity receptor FcεRI. Antigen-specific IgE binds with high affinity to FcϵRI, 
and in the presence of a specific antigen, these complexes aggregate. Aggregation of 
only a small fraction of the FcεRI on the mast cell is sufficient to trigger mast cell 
activation and mediator secretion, and thus individual mast cells can be simultaneously 
sensitized to respond to many different specific antigens  (Galli and Tsai 2010).  
Experimentally, IgE cross-linkage may be induced artificially by the use of anti-IgE 
antibodies or antibodies against the IgE receptor  (Metcalfe et al. 1997). The FcεRI 
exists in two forms. It can be expressed as a trimer or tetramer comprising of an IgE-
binding α-chain, a membrane-tetraspanning β-chain that is absent in the trimeric 
receptor, and a disulfide-linked homodimer of γ-chains  (Rivera et al. 2008). IgE binds to 
the extracellular domain of the α-subunit, the γ homodimer is indispensable for the 
generation of the signals required for mast cell activation and the β-chain appears to 
serve primarily as a modulator of the signals regulated by the γ-chains. (Metcalfe et al. 
2009). In mast cell activation the aggregation of the IgE-FcεRI initiates a multi-step, 
intracellular signaling pathway which  is both up-regulated and down-regulated by  
several intracellular molecules. While the exact role of many of these components is 
still unclear, the precise cooperation of the signaling molecules in the pathway is 
required for eliciting full functional responses of mast cells. (Rivera et al. 2008).  
In addition to FCεRI, mast cells express several types of FCγ-receptors for IgG in both 
human and rodent mast cells. Human mast cells express FcγRI and FcγRII while mouse 
40µm 
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mast cells express FcγRII and FcγRIII (Xu and Shi, 2012). These murine Fc-gamma 
receptors bind IgG with a low affinity and the cross-linking of FcγRIII triggers the release 
of TNF-α  (Latour et al. 1992).  Interestingly, the IgE-FcεRI induced mast cell activation 
can be inhibited by cross-linking FCεRI to low-affinity FcγRII by the same multivalent 
ligand  (Daeron et al. 1995). This receptor aggregation leads to phosphatase SHIP-1 
mediated pathway down-regulation and inhibits calcium influx and downstream 
responses normally resulting in mast cell activation  (Ono et al. 1996).  
In addition to IgE and antigen immunoglobulins, anaphylatoxins, hormones, 
neuropeptides, cytokines and some polybasic molecules can trigger mast cell secretion 
in a manner independent of FcεRI. Members of these polybasic molecules include 
C48/80, mastoparan, polymyxin B, and polymers of basic amino acids. These polybasic 
secretagogues induce mast cell activation and granule exocytosis by a common 
mechanism and share similar structures. The most important feature is the existence of 
a cationic cluster at one side of a hydrophobic moiety. This may be an α-helical 
structure (mastoparan, substance P, and other peptides) or an aromatic ring (C48/80). 
These molecules activate mast cells by interacting with the same site on mast cells in a 
non-cytotoxic manner without binding to a specific receptor. C48/80 merges with the 
cell membrane and remains attached to it, its aromatic rings inserted into the cell 
membrane.  The positively charged domain of C48/80 interacts with intracellular G 
proteins resulting in promotion of GDP/GTP exchange similar to the effect of a ligand 
occupied receptor. (Metcalfe et al. 1997). Also various physiological responses, through 
respective hormones and mediators, such as hypoxia  (Jin et al. 2009) and stress  
(Huang et al. 2002) can induce mast cell activation.  
All of the above features underlie the multifunctional nature of mast cells. The relative 
composition and amount of mediators released from activated mast cells and the 
degree, to which they home to sites of inflammation, can be profoundly influenced by 
the extent to which surface receptors interact to engage alternative and 
complementary intracellular signaling pathways (Gilfillan and Tkaczyk 2006). The extent 
and duration of mast cell activation is the result of the complex interplay between the 
activating and inhibiting factors present in the host tissue of the mast cell.  
 2.4. Mast cell mediators 
The activation of mast cells results in three types of biologic effects. First, mast cells 
undergo regulated secretion in which preformed contents stored in their granules are 
rapidly released by exocytosis. Mediators released include histamine, proteoglycans, 
proteases and cytokines. The release of granule content is followed by enzymatic 
synthesis of lipid mediators derived from precursors stored in cell membranes and in 
lipid bodies. Last mast cells initiate transcription, translation and secretion of a diverse 
array of cytokines and expression of certain chemokines resulting in a release of these 
de novo synthesized molecules several hours after the initial stimulation (Mekori and 
Metcalfe 2000). The process of mast cell degranulation occurs within seconds, at least 
after immunological activation and the initial rapid phase is essentially complete within 
5–10 minutes (Gilfillan and Beaven 2011). The second-wave production of de novo 
synthesized molecules, however, sustains and amplifies the initial response, beginning 
2-4 hours after the original challenge and peaking between 6 and 12 hours afterwards 
(Metcalfe et al. 1997, Benoist and Mathis 2002). The vast variety of mast cell mediators 
reflects the role of the mast cells in many physiological and pathophysiological events 
(Table 1).   
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Table 1. Mast cell mediators (modified from Theoharides et al., 2012)* 
Mediator Main Pathophysiologic Effects 
Biogenic amines  
 Histamine Vasodilation, angiogenesis, mitogenesis, pain 
 Serotonin Vasoconstriction, pain 
 Dopamine Neurotransmitter 
Enzymes  
 Arylsulfatases Lipid/proteoglycan hydrolysis 
 Carboxypeptidase A Peptide processing 
 Chymase Tissue damage, pain, angiotensin II synthesis 
 Kinogenases Synthesis of vasodilatory kinins, pain 
 Phospholipases Arachidonic acid generation 
 Tryptase Tissue damage, activation of PAR, inflammation, pain 
 Matrix metalloproteinases Tissue damage 
Proteoglycans 
 Chondroitin sulfate Cartilage synthesis, anti-inflammatory 
 Heparin Angiogenesis, nerve growth factor stabilization 
 Hyaluronic acid Connective tissue, nerve growth factor stabilization 
Cytokines  
 TNF-α, IL-8, IL-4, IL-15 Inflammation 
 VPF/VEGF, bFGF Neovascularization, cell growth 
 MCP-3(CCL7),MCP-1(CCL2), MCP-4, 
RANTES (CCL5), Eotaxin (CCL11) 
Chemoattraction and tissue infiltration of leukocytes 
Other peptides  
 Angiogenin Neovascularization 
 Corticotropin-releasing hormone Inflammation, vasodilation 
 Kinins (bradykinin) Inflammation, pain, vasodilation 
 Renin Angiotensin synthesis 
 Urocortin Inflammation, vasodilation 
 Vasoactive intestinal peptide Vasodilation, mast cell activation 
 Hyaluronic acid Connective tissue, nerve growth factor stabilization 
De novo synthesized 
Cytokines  
 IL-1,2,3,4,5,6,8,9,10,13,16,18 Inflammation, leukocyte migration, pain 
 IFN- α , IFN-β, IFN-γ,MIF, TGFβ, TNF-α Inflammation, leukocyte proliferation/activation 
 MIP-1α, MCP-1  
Growth Factors  
 SCF, GM-CSF, β-FGF, neurotrophin 3, 
NGF 
Growth of a variety of cells 
 PDGF, TGFβ, VEGF  
Nitric oxide Vasodilation 
Phospholipid metabolites 
 Leukotriene B4 Leukocyte chemotaxis 
 Leukotriene C4 Vasoconstriction, pain 
 Platelet activating factor Platelet activation, vasodilation 
 Prostaglandin D2 Bronchonstriction, pain 
bFGF, basic fibroblast growth factor, β-FGF, β-fibroblast growth factor; BGM-CSF, granulocyte 
monocyte-colony stimulating factor; IFNγ, interferon-γ; IL, interleukin; MCP, monocyte 
chemoattractant protein; MIF, macrophage inflammatory factor; MIP, macrophage inflammatory 
protein; NGF, nerve growth factor; PAR, protease-activated receptor; PDGF, platelet-derived growth 
factor; SCF, stem cell factor; TGFβ, transforming growth factor β ; TNF-α, tumor necrosis factor-α; 
VPF/VEGF, vascular permeability factor/vascular endothelial growth factor *There are differences in 
the expression of mediators between human and rodent mast cells.  
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2.4.1. Stored mediators 
Biogenic amines 
Histamine is the major amine stored in human mast cells but rodent mast cells also 
contain significant quantities of 5-hydroxytryptamine (5HT, serotonin) within their 
granules  (Nautiyal et al. 2012).  
Histamine and its effects can be seen in all parts of the body. The majority of histamine 
is stored in granules of mast cells although histamine is also found in basophils, 
lymphocytes, enterochromaffin, and endothelial cells, as well as in neurons (Pesonen 
2007). On release, histamine diffuses rapidly through tissues and the circulatory system 
but does not penetrate the central nervous system (Gilfillan and Beaven 2011). Within 
minutes of release, histamine is metabolized into methylhistamine, methylimidazole 
acetic acid, or imidazole acetic acid. It is thus likely that histamine usually influences 
events at or near the site of release (Metcalfe et al. 1997). Histamine exerts its 
functions via four known G protein-coupled receptors, H1R, H2R, H3R and H4R, which 
possess divergent downstream signaling effects. H1R and H2R have wide distribution 
and are present on many cells. H3R is expressed in the central and peripheral nervous 
system, where it serves as a presynaptic feedback receptor on histaminergic neurons. 
H4R is a recently identified receptor possessing a more limited expression that includes 
several specific subsets of immune cells  (Smuda and Bryce 2011). The distribution of 
histamine receptors and the physiological responses mediated through these receptors 
are portrayed in detail in Table 2.  Mast cell dependent histamine is best known for its 
effects in acute allergic and anaphylactic reactions. These effects are mainly mediated 
through histamine receptors H1R and H2R located on bronchial smooth muscle and 
endothelial cells or on vascular smooth muscle and gastric parietal cells, respectively. 
The primary physiological effects of histamine release from mast cells are thus 
increased vascular permeability, vasodilatation, and bronchial constriction, which are 
readily reversed by antihistamines (Gilfillan and Beaven 2011). Antihistamines are 
specific H1R antagonists selectively blocking the histamine effects conveyed through 
H1-receptors. Antihistamines efficiently block the rash and itching symptoms caused by 
increased permeability in the skin. H2R antagonists are commonly used as drugs 
against acidic gastric symptoms. H2R antagonists block the secretion of gastric acid 
from parietal cells and accelerate the healing of gastric ulcers (Pesonen 2007). 
Rodent mast cells contain significant quantities of serotonin and it appears to be a 
minor component in human mast cells as well. Serotonin induces inflammatory skin 
reactions, including increased permeability, in mice (Inoue et al. 1995) and 
bronchoconstriction in rats (Krop et al. 2010) and these effects are blocked by 
serotonin receptor specific antagonists. It has also been recently shown that mast cell 
deficiency resulting in subnormal serotonin levels leads to disrupted hippocampus-
dependent behavior and neurogenesis (Nautiyal et al. 2012).   
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Table 2. Histamine receptor subclasses, location and effects of receptor stimulation (modified from 
Pesonen, 2007) 
Receptor Location of receptor Physiological response  
H1 Smooth muscle  Smooth muscle contraction (bronchi, intestine, blood 
vessels) 
 Endothelial cells  Increase of vascular permeability, increase of NO 
formation, contraction of endothelial cells 
 Immunological cells Increase of eosinophil and neutrophil chemotaxis   
 Adrenal cortex Stimulation of hormonal secretion 
 Heart Negative dromotropic and inotropic effect  
 CNS Excitatory effect on neuron activation, regulation of 
circadian rhythm, reduces appetite  
H2 Gastric parietal cells Increase of acid secretion 
 Smooth muscle cells Relaxation of smooth  muscle cells (uterus, blood 
vessels) 
 Immunological cells Decrease in lymphocyte function, decrease of 
eosinophil and neutrophil chemotaxis , decrease in 
cytokine production  
 Heart Positive inotropic and chronotropic effect  
 CNS Blocking of Ca
2+
 channels  
H3 CNS  
Peripheral nervous system 
Blocking of the release of presynaptic histamine 
(autoreceptor), blocking of histamine synthesis, 
blocking of histamine neurons  
H4 BM, HPCs Differentiation of myeloblasts and promyeloblasts  
 Immunological cells Increase of MC and eosinophil chemotaxis, increased 
infiltration of inflammatory cells to affected tissue  
BM, bone marrow; CNS, central nervous system; HPCs, hematopoietic cells; MC, mast cell; NO, 
nitrogen oxide 
 
Proteoglycans 
A hallmark morphological feature of mast cells is their large content of cytoplasmic 
secretory granules, filled with numerous secretory compounds, including highly 
negatively charged heparin or chondroitin sulfate proteoglycans of serglycin type. 
Heparin is the main component (~30% of the dry weight) of granules isolated from rat 
peritoneal mast cells. (Ronnberg et al. 2012). Proteoglycans act as extracellular 
mediators and as storage matrices for other preformed mast cell mediators that might 
otherwise have deleterious effects on the mast cell itself (Metcalfe et al. 1997). 
Importantly, in mast cell granules, chymase enzyme is attached to heparin which gives 
it partial resistance against its natural inhibitors by hindering the attachment of 
inhibitors to the active part of enzyme once released from mast cells (Pejler and Berg 
1995, Lindstedt et al. 2001).  Mast cell proteoglycans have an essential role in 
promoting the storage of other granule-contained compounds including bioactive 
monoamines and different mast cell-specific proteases. Heparin is also a potent 
anticoagulant, it has limited anti-inflammatory and vasodilation effects and it efficiently 
reduces post-prandial hyperlipemia (Kallio 2007). The macromolecular heparin 
proteoglycans from rat serosal mast cells strongly inhibit platelet-collagen interactions 
(Lassila et al. 1997). 
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Enzymes 
Mast cells contain a variety of enzymes which can be further divided to neutral granule 
proteases and acidic lysosomal enzymes. The neutral granule proteases constitute 
between 30–50% of the total protein content of mast cells thus in terms of mass, they 
represent the major group of mediators released by exocytosis  (Gilfillan and Beaven 
2011). Mast cells in different species and at different stages of development express 
varied combinations of granule proteases. The granule proteases fall into three classes, 
tryptases, chymases, and carboxypeptidase A. Chymase and tryptase are involved in a 
variety of functions, both harmful and protective. The role of mast cell proteases in 
atherosclerosis will be discussed in a following chapter. 
Chymase is an enzyme expressing chymotrypsin-like activity. Based on their structural 
homologies, chymases are divided to two groups, α- or β- chymases. α-chymases are  
expressed in most mammals, including primates, canines, ruminants, and rodents. In 
humans, only one chymase gene, belonging to the α-chymase family has been 
identified. β-chymases, however,  are rodent-specific. (Caughey 2004).  Comparison of 
human and rodent mast cell proteases is presented in Table 3. Mice and rats have 
numerous β-chymases. Mouse mast cells express three β-chymases, mouse mast cell 
protease-1 (mMCP-1), mMCP-2, mMCP-4, as well as one α-chymase, mMCP-5  
(Tchougounova et al. 2003). Based on sequence similarity, mMCP-5 is the closest 
homolog to human chymase. mMCP-5, the only α-chymase together with rat mast cell 
protease 5 (rMCP-5) however, have a unique biological activity different from the 
chymases of other species. mMCP-5 and rMCP-5 are elastase-like proteases, not 
chymotrypsin-like proteases. (Kunori et al. 2002). mMCP-1 and mMCP-2 both have 
different tissue distribution and enzymatic activities than human chymase. The 
functional homolog for human chymase is mMCP-4 which has a highly similar substrate 
activity and tissue distribution than that of human chymase  (Pejler et al. 2010). mMCP-
4 also constitutes the major chymotrypsin-like activity in mouse peritoneum and ear 
tissues  (Tchougounova et al. 2003). Rat mast cells contain four β-chymases, rMCP1-4 
and one α-chymase, rMCP-5. Mouse and rat mast cells show a high degree of similarity 
in their protease expression. CTMCs of both species express two dominant chymases, 
rMCP-1/mMCP-4 and rMCP-5/mMCP-5, which are homologues to each other. 
(Lutzelschwab et al. 1997).  In addition, rat mast cells express rMCP-3 widely in MMCs 
and CTMCs, with predominance in CTMCs (Ide et al. 1995). When comparing MMCs of 
the two species, there are similarities in the protease content and they both express 
mainly one chymase RMCP-2/MMCP-1. No specific counterpart for mMCP-2 has been 
found in rat mast cell proteases and no counterpart for rMCP3 and rMCP4 is yet known 
in mouse mast cell proteases. (Lutzelschwab et al. 1997).   
Chymase specificity is chymotrypsin-like; protein and peptide targets are cleaved 
preferentially after aromatic amino acid residues from the carboxyl-terminal end of 
peptides or proteins (Pejler et al. 2010). Chymase is active at neutral to alkaline pH, 
thus chymase activity in the granules is limited by the low intracellular pH and chymase 
becomes fully active only after the release into the neutral pH environment outside the 
cell.  Although chymases are known to act on various pathophysiological settings, no 
truly specific in vivo substrates are known.  Mast cell chymases destroy extracellular 
matrix proteins, activate matrix metalloproteinase, potentiate plasma leakage, 
stimulate submucosal gland cell secretion, inactivate inflammatory neuropeptides, 
catabolize lipoproteins, control complement mediated inflammation, promote 
angiogenesis, and generate extravascular angiotensin II(AngII). (Caughey 2004). 
Chymase also has a beneficial role in host defense against parasitic and bacterial 
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infections (Pejler et al. 2010). Solubilized chymases are inhibited by various serpins 
such as α1-antichymotrypsin as well as other inactivators including soybean trypsin 
inhibitor and chymostatin (Caughey 2004). Some of the chymase inhibitors have been 
used to ameliorate experimentally induced diseases successfully (Pejler et al. 2010).  
Table 3. Neutral mast cell proteases in human, mouse and rat 
Species MC subclass Tryptases Chymases MC-CPA 
Human MCT α   
  β (I, II, III)   
 MCTC α CMA-1 (α) MC-CPA 
  β (I, II, III)   
Mouse MMC  mMCP-1   
   mMCP-2  
 CTMC mMCP-6 mMCP-4 MC-CPA 
  mMCP-7 mMCP-5 (α)  
   mMCP-9  
Rat MMC  rMCP-2  
   rMCP-3*  
   rMCP-4  
 CTMC rMCP-6 rMCP-1 MC-CPA 
  rMCP-7 rMCP-3  
   rMCP-5 (α)  
Human mast cells secrete α- and β-tryptases (βI-III) upon activation. Rat and mouse tryptases 
r/mMCP-6 and -7 are the counterparts for human α- and β-tryptase. Human mast cells express only 
one chymase gene and its functional murine and rat counterparts are represented in the table in bold 
letters. Rodent mast cells express α- and β-chymases. There is only one α-chymase gene expressed on 
mouse and rat mast cells and they are marked in the table.  * rMCP-3 is expressed both in MMCs and 
CTMCs but found mainly in CTMCs. Data derived from Ide et al., 1995, Lützelschwab et al., 1997, 
Pejler et al., 2010.  
 
 
Tryptases are a subgroup of trypsin-family serine peptidases with shared enzymatic, 
structural, and phylogenetic features. Tryptases have a trypsin-like target preference, 
cleaving their peptide and protein substrates at lysine and arginine residues. Humans 
express two main enzymatically active tryptases that are secreted as tetramers, α- and 
β-tryptases (βI-III). The murine tryptases (mMCP-6 and mMCP-7) are also tetrameric 
and constitute the counterpart for human α- and β-tryptases (Pejler et al. 2010). Rat 
tryptases rMCP-6 and rMCP7 are homologs of the respective mouse counterparts 
(Lutzelschwab et al. 1997).  Dogs, pigs and mice express an additional mast cell 
tryptase-like enzyme, mastin (in mice also known as MCP-11/Prss34) (Caughey 2007). 
In humans, the level of mature β-tryptase in the bloodstream is normally low or 
undetectable, but rises dramatically after anaphylaxis and therefore β-tryptase in the 
bloodstream is used as a marker of anaphylaxis before and after death (Caughey 2004).  
Tryptases have many pro-inflammatory functions and  tryptase itself is able to promote 
histamine release and therefore may help to spread the degranulation signal from one 
group of activated mast cells to others. Tryptases can provoke inflammatory responses 
from airway epithelial cells (Caughey 2007) and amplifiy the pathological changes and 
increase the levels of proinflammatory markers in chemically induced acute colitis 
(Hamilton et al. 2011). Tryptases have also anti-inflammatory functions. Tryptases have 
been shown to contribute in the innate immune response towards Trichinella spiralis 
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and to the defense against intraperitoneal Klebsiella pneumoniae infection (Pejler et al. 
2010).  
Cytokines 
Mast cells are a source of a huge spectrum of cytokines and chemokines, which are 
protein or glycoprotein molecules synthesized and secreted by cells. Some cytokines 
can be stored in granules in a preformed fashion. One of these cytokines is TNF-α which 
contributes to host defense, the pathophysiology of allergic diseases and other 
processes dependent on TNF-α (Gordon and Galli 1990). TNF-α is also synthesized de 
novo and the amount and the effects mediated through the preformed TNF-α are 
minimal compared to the de novo-generated (Gilfillan and Beaven 2011). Mouse mast 
cells also release vascular permeability factor/vascular endothelial cell growth factor 
(VPF/VEGF) which both potently enhance vascular permeability and induce 
proliferation of vascular endothelial cells (Boesiger et al. 1998). Mast cells store, bound 
together with heparin, a potent angiogenic and mitogenic polypeptide, basic fibroblast 
growth factor (bFGF) (Qu et al. 1995). Mast cell-derived bFGF is a chemical mediator 
involved in tissue injury response through chemotaxis and cellular proliferation (Reed 
et al. 1995). 
2.4.2. Newly synthesized mediators 
Cytokines 
Mast cells generate a wide variety of both cytokines such as IL-3, IL-4, IL-5, IL-6, IL-10, 
IL-13, IL-33, GM-CSF and TNF-α and chemokines including CCL2, CCL3, and CCL5. 
However, in contrast to degranulation and eicosanoid release, this is a delayed process 
taking several hours before significant levels of cytokines and/or chemokines are 
detected to be secreted from activated mast cells (Gilfillan and Beaven 2011). The 
types of cytokines produced are not fixed. The presence of different growth factors and 
external cytokines in the extracellular environment changes the cytokine profile in the 
mast cells. The release of mast cell cytokines can also be achieved without mast cell 
degranulation. (Theoharides et al. 2007). This suggests that cytokines and granule 
components have evolved to play different roles in the defense mechanisms against 
parasites, toxins and other harmful bioactive agents and organisms. Nevertheless, 
along with granule components, secreted cytokines manifest pathophysiology 
associated with allergic inflammation and may also contribute to angiogenesis and 
cellular hyperplasia associated with tumorigenesis although the biological relevance of 
many of these cytokines is still unclear. (Beaven 2009, Gilfillan and Beaven 2011). 
Phospholipid metabolites 
The activation of mast cells causes the initiation of the de novo synthesis of lipid-
derived substances also referred as eicosanoids, signaling molecules conveying many 
physiological responses, mainly in inflammation and immunity. The initiating process in 
the generation of eicosanoids is receptor-mediated activation of phospholipase (PL) A2 
which produces free arachidonic acid through hydrolysis of arachidonyl-containing 
phospholipids. Arachinoid acid is subsequently metabolized through the actions of 5-
lipoxygenase and cyclo-oxygenase to respectively generate leukotrienes (LTs) and 
prostaglandins (PGs.) (Gilfillan and Beaven 2011). PGs such as PGD2 are generated after 
the immunologic activation of human mast cells. PGD2 is a potent inhibitor of platelet 
aggregation and it is chemokinetic for human neutrophils. LTs induce a prolonged 
cutaneous wheal-and-flare response, stimulate prolonged bronchoconstriction, 
enhance vascular permeability, promote bronchial mucus secretion, and induce 
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constriction of arterial, arteriolar, and intestinal smooth muscle. Platelet activating 
factor (PAF) has been detected after activation of mouse bone marrow-derived mast 
cells, rabbit basophils, and human mast cells. PAF aggregates and degranulates 
platelets, induces wheal-and-flare reactions in human skin, increases lung resistance 
and leads to systemic hypotension. (Metcalfe et al. 1997).  
In conclusion, the extensive repertoire of mast cell mediators reflects the 
multifunctional role of mast cells in inflammation and innate immunity. Mast cell 
mediators vary between tissues and their roles can be anti-inflammatory or pro-
inflammatory in nature. The role of mast cells can also change during the mast cell 
activation process thus shifting from a useful, well-intentioned immune response to a 
harmful effect making it a difficult task to predict the outcome of the mast cell 
activation. 
 
2.5.Mast cell function 
The eclectic cocktail of mast cell mediators released upon mast cell activation and their 
extensive distribution in almost all tissues reflects the multitude of mast cell functions. 
Traditionally, mast cells are considered major effectors in IgE-associated immediate 
hypersensitivity and in allergic responses such as asthma (Anand et al. 2012). However, 
changes in mast cell numbers in various anatomic sites and/or evidence of 
degranulation have been observed in a wide spectrum of innate, adaptive, and 
pathological immune responses and in a large number of diseases or disease-related 
processes, including delayed hypersensitivity reactions, fibrosis, autoimmune 
pathology, neoplasia, inflammation in the rheumatoid synovium and inflammatory 
bowel diseases  (Metcalfe et al. 1997).  
Mast cell function and mast cell activation are often associated with the harmful, or 
even lethal, effects they convey, as is the case with anaphylaxis. Mast cells are, 
however, inflammatory cells involved in host defense and they have a protective role 
against many outside chemical and biological threats. Studies on mast cell-deficient 
and designated mast cell protease-deficient mice have shown that these mice have 
decreased innate immune responses against parasitic and bacterial infections 
compared to wild-type mice. One mast cell dependent protecting mediator is mMCP-1, 
a mouse mast cell chymase essential for fighting parasitic infections. The deletion of 
the mMCP-1 gene is associated with significantly delayed expulsion of the nematode 
Trichinella spiralis and increased deposition of muscle larvae in mice despite the 
presence of normal and sometimes increased numbers of MMCs. (Knight et al. 2000). 
Mast cell deficiency results in decreased mast cell dependent cytokine production 
leading to an increased parasite burden following infection with gastrointestinal 
helminthes which suggests that mast cells are involved in the early innate events that 
determine the priming of adaptive immunity (Hepworth et al. 2012). Another mast cell 
dependent protector is mMCP-6, a mouse mast cell tryptase. The mMCP-6 deficient 
mice, despite having normal MC numbers, morphology and secretory responses and 
intact FcϵRI-dependent reactions, exhibit a substantially reduced ability to resist 
Chlamydia pneumoniae infections in their peritoneal cavities. The survival rate for 
these mice is reduced to a mere 10%, while the wild-type mice have a survival rate of 
80%  (Thakurdas et al. 2007). Co-culture of peritoneal mast cells together with 
Staphylococcus aureus has been shown to produce a range of pro-inflammatory 
cytokines in vitro but it seems that the mast cells do not exhibit protection against S. 
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aureus infection in vivo (Ronnberg et al. 2014). Mast cells are also involved in the 
protection of bacterial skin infections. Mast cell deficiency leads to a deferred 
clearance of the bacteria Pseudomonas aeruginosa from skin lesions and an impaired 
neutrophil recruitment (Siebenhaar et al. 2007). Mast cells thus play a crucial 
protective role, at least in animal models, against systemic and localized bacterial 
infections. Mast cells are also activated, at least in vitro, by viral components. The role 
of mast cells in innate immunity against viral infections is yet not fully understood but 
mast cell deficiency is involved at least in a decreased CD8+ T recruitment in 
experimental Newcastle disease virus (NDV) infection (Orinska et al. 2005). 
Interestingly, despite the infamous reputation of mast cells in anaphylaxis, mast cells 
can protect against and enhance the odds of survival from an exposure to snake and 
honeybee venom. Mast cells mediators are able to break down sarafotoxin, the most 
toxic component of many snake venoms. Mast cell-deficient mice exhibit significantly 
higher levels of circulating toxins and decreased survival rates compared to mast cell 
sufficient mice after experimental administration. (Metz et al. 2006). Another potential 
protective role for mast cells is the use of mast cell-derived components or mast cell 
activating compounds as vaccine adjuvants resulting in a stronger antigen specific 
immune response (Kurashima and Kiyono 2014).  
Mast cells are involved in a variety of pathological conditions. The best known of these 
are the IgE-dependent allergic reactions known as the type I or immediate 
hypersensitivity reactions. Anaphylaxis is the most extreme outcome of IgE-dependent 
mast cell activation resulting in the worst case to death. Along with the IgE-dependent 
systemic mast cell activation, anaphylaxis-like pathological condition can be triggered 
artificially by administration of C48/80  (Kim et al. 2006). Upon activation, mast cells 
quickly release the preformed granule stored mediators and these mediators are 
believed to be responsible for the pathophysiology of anaphylaxis. Histamine 
stimulates vasodilation, and increases vascular permeability, heart rate, cardiac 
contraction; PGD2 is a bronchoconstrictor, pulmonary and coronary vasoconstrictor; 
leukotrienes produce bronchoconstriction, increase vascular permeability, and 
promote airway remodeling; PAF is a potent bronchoconstrictor and increases vascular 
permeability and TNF-α activates neutrophils, recruits other effector cells, and 
enhances chemokine synthesis. These physiological effects contribute to the overall 
pathophysiology of anaphylaxis that presents with generalized urticaria and 
angioedema, bronchospasm and other respiratory symptoms, hypotension, syncope 
and other cardiovascular symptoms and nausea, cramping, and other gastrointestinal 
symptoms. (Peavy and Metcalfe 2008). Other type I hypersensitivity reactions include 
allergic asthma, rhinitis, conjunctivitis, atopic dermatitis and food allergies (Gilfillan and 
Beaven 2011). 
Mast cells are also involved in the pathophysiology of autoimmune disorders including 
rheumatoid arthritis (RA) and multiple sclerosis (MS). In RA models mast cells 
accumulate and release their granule content resulting in the accumulation of other 
inflammatory cells, breakdown of extracellular matrix in the synovial joint and the 
progression of the disease seem to be dependent on the functionality of mast cells 
(Getting et al. 1997, Gilfillan and Beaven 2011, Anand et al. 2012). Mast cell-derived IL-
1β also complicates the early stages of monosodium-urate crystal-induced acute 
arthritis in mice (Reber et al. 2014). Experimental autoimmune encephalomyelitis (EAE) 
in mice is the counterpart for human MS. In both diseases mast cells are found in 
increased numbers within and outside MS lesions in the brain and mast cell deficient 
mice exhibit significantly less severe EAE that can be restored to wild-type levels by 
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BMMC reconstitution (Anand et al. 2012). Elevated mast cell tryptase levels can be 
detected in the cerebrospinal fluid of MS patients giving further proof of the 
involvement of mast cell activation in MS (Rozniecki et al. 1995). Other autoimmune 
disorders thought to be mast cell related include type 1 diabetes, Guillain-Barré 
syndrome, scleroderma, ulcerative colitis, Crohn’s disease, Sjögren’s syndrome, Graves’ 
eye disease and chronic idiopathic urticaria (Gilfillan and Beaven 2011).  
As mast cells are known to release several angiogenic factors including fibroblast 
growth factor-2 (FGF2), VEGF, TGFβ, IL-8, histamine, heparin, and angiopoietin 1 the 
role of mast cells in wound healing and tumor growth seems expected. Mast cells 
accumulate along edges of healing wounds, scar tissue, keloids, and hypertrophic scars, 
and can produce fibroblast as well as keratinocyte growth factors in addition to matrix 
remodeling factors (Gilfillan and Beaven 2011). Mast cells have an important role in 
dermal scarring and activated mast cells are associated with scarring and fibrosis and 
animals lacking mast cells have been shown to heal with reduced scar tissue (Wilgus 
and Wulff 2014). The role of mast cells in tumor genesis is controversial and both pro- 
and anti-tumorigenic roles are described (Theoharides and Conti 2004). The mast cell-
derived mediators, such as histamine, tryptase, bFGF, VEGF, and IL-8, are shown to 
enhance tumor growth and angiogenesis while on the other hand, mast cell-derived 
TNF-α and heparin are shown to act as tumor suppressors (Anand et al. 2012).  
Apart from these pathological conditions mast cell involvement is associated with male 
infertility, anxiety, Alzheimer’s disease and nociception. Mast cells have also 
detrimental effects in viral infections. Mast cell dependent vasoactive products, 
leukotrienes and chymase are released from activated mast cells in vivo during Dengue 
virus infection and this promotes vascular leakage further complicating the disease (St 
John et al. 2013). The versatile biological functions of mast cells described in this 
chapter all portray the complex role of mast cells having both positive and negative 
role for the host. In many diseases the use of mast cell stabilizers would seem tempting 
but the use of these stabilizers would also inhibit the anti-inflammatory effects of mast 
cells and could potentially expose the host to otherwise harmless infections.  
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3. Mast cells and atherosclerosis 
Atherosclerosis is chronic inflammatory disease of the arterial wall characterized by 
formation of atherosclerotic plaques consisting of necrotic core, accumulated modified 
lipids, inflamed smooth muscle cells, endothelial cells and inflammatory cells such as 
leukocytes, macrophages and mast cells (Galkina and Ley 2009). The lesions of 
atherosclerosis occur primarily in large and medium-sized elastic and muscular arteries 
and can lead to ischemia of the heart, brain, or extremities, resulting in infarction (Ross 
1999). The earliest changes of atherosclerotic lesions can appear early in life. LDL 
oxidation and formation of fatty streaks may occur already during fetal development, 
and both phenomena are greatly enhanced by maternal hypercholesterolemia. 
Furthermore, LDL accumulation and oxidation appear to contribute to 
monocyte/macrophage recruitment early on. (Napoli et al. 1997). In persons with 
hypercholesterolemia, the influx of the inflammatory cells is preceded by the 
extracellular deposition of amorphous and membranous lipids (Ross 1999). Finally, in 
the advancing disease the recruitment and activation the various inflammatory cells 
can affect the modification and progression of atherosclerotic lesions.  
 
 3.1. Mast cells and mast cell activation in atherosclerotic lesions 
Mast cells were first linked to atherosclerosis more than 50 year ago by Constantidines 
(1953). He suggested that mast cells might have a protective role against 
atherosclerosis. Since then the role of mast cells has been defined and versatile 
functions for mast cells in the progression of atherogenesis have been suggested. Mast 
cells are found in the atherosclerotic lesions and their phenotypes (MCT or MCTC) vary 
between individuals  (Kaartinen et al. 1994A, Kaartinen et al. 1994B). Mast cells are 
found at the site of foam cell formation and at the growing edge of atheromas 
suggesting that mast cells play a role in the early and late stages of atherogenesis  
(Kaartinen et al. 1994A). In fatty streaks of the human arterial intima the proportion of 
mast cells of the total number of all nucleated cells is 9-folds higher than in normal 
coronary intima and the and level of mast cell activation is almost 5 times higher than 
in normal intima (Kaartinen et al. 1994B). Furthermore, the level of activated mast cells 
is increased by more than 200-fold at site of atheromatous erosion or rupture  
compared to un-affected coronary intima indicating the involvement of mast cells in 
thrombotic coronary occlusion (Kovanen et al. 1995). Mast cells are also found in the 
hearts of spontaneously hypertensive rats and the number of mast cells and the levels 
of mast cell mediators are increased when cardiac hypertrophy is advanced (Shiota et 
al. 2003). In LDLR deficient mice prone to atherosclerosis, mast cell activation increases 
the area of atherosclerotic lesions, as wells as plasma total cholesterol, LDL, and 
triglyceride levels, whereas mast cell stabilization reduced these parameters (Wang et 
al. 2013). Mast cell activation in apoE-deficient mice leads to intraplaque hemorrhage, 
macrophage apoptosis, vascular leakage and leukocyte recruitment in the plaque all of 
which can be prevented by mast cell stabilizers (Bot et al. 2007). 
Patients with dyslipidemia (levels of non-HDL cholesterol >5.2 mmol/L) have increased 
serum IgA, IgE and IgG levels and dyslipidemia together with increased immunoglobulin 
levels is associated with increased risk myocardial infarction and cardiac death  
(Kovanen et al. 1998).  Since IgE in tissues can induce homing of mast cell progenitors 
to these tissues (Collmann et al. 2013), increased serum IgE levels correlate with the 
density of IgE receptors of mast cells (Saini et al. 2000) and IgE-antibody complexes 
activate mast cells, it can be presumed that mast cells are activated locally in the heart 
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through IgE-dependent activation. IgE and its receptor FcεRI are present in human 
atherosclerotic lesions at least at macrophage-rich areas. Cultured macrophages, aortic 
smooth muscle cells and endothelial cells exhibit IgE-induced signal transduction, 
inflammatory molecule expression, and apoptosis (Wang et al. 2011) Neuropeptides 
such as substance P also activate mast cells, and substance P-containing sensory nerves 
are in contact with adventitial mast cells in human coronary arteries (Laine et al. 2000). 
Mice lacking the substance P gene have improved cardiac function in a volume 
overload model and administration of substance P to the adventitia of mice prone to 
atherosclerosis, induce intraplaque hemorrhage which was prevented in mice lacking 
mast cells. (Kennedy et al. 2013). In addition, different risk factors traditionally 
associated with increased risk of atherosclerosis can also induce mast cell activation. 
Stress can escalate acute coronary syndrome but physiological stress can also induce 
cardiac mast cell activation and after exposure to restraint stress, histamine release 
from cardiac mast cells is significantly increased in mice with experimentally induced 
atherosclerosis, compared to normal mice, due to increased mast cell density in the 
heart of affected animals  (Pang et al. 1998, Huang et al. 2002). Oxidized LDL, found in 
atherosclerotic plaques forms complexes with IgE and these complexes activate mast 
cells in vitro  (Lappalainen et al. 2011). In addition, pro-atherogenic bacteria Chlamydia 
pneumoniae and Aggregatibacter actinomycetemcomitans induce mast cell activation 
and the release of pro-inflammatory cytokines in cultured human connective tissue-
type mast cells and activate mouse aortic mast cells in vivo  (Oksaharju et al. 2009). All 
of the above mechanisms can be involved in the activation of mast cells in the 
progression of atherosclerosis but no single endogenous activator solely responsible for 
mast cell activation is known.  Mast cell activation leads to the release of mast cell 
proteases and inflammatory cytokines which induce neighboring cell protease 
expression and leads to vascular wall subendothelium disruption and further blood-
borne leukocyte transmigration (Xu and Shi 2012). Mast cell histamine release leads to 
disruption of endothelial barrier and allows the local influx of macromolecules present 
in blood to the interstitium. This can result in the local accumulation of atherogenic 
lipoproteins further complicating the inflammation atherosclerosis. 
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3.2. Role of mast cell proteases in atherosclerosis 
Mast cell proteases make up a group of variable enzymes with a vast number of 
substrates. Mast cells are rich in matrix metalloproteinases (MMP), cysteine protease 
cathepsins, serine proteases urokinase, plasmin, and cathepsin G and they contain their 
unique neutral serine proteases, chymases, and tryptases. Serum tryptase level has a 
positive correlation to metabolic syndrome parameters such as body mass index and 
fasting serum triglycerides and a negative correlation to serum HDL levels. Serum 
tryptase levels are higher in patients with a carotid plaque formation and serum 
tryptase level itself contributes independently to subclinical atherosclerosis. (Moreno 
et al. 2014). Similarly it has been shown that serum chymase levels tend to be higher in 
patients with acute myocardial infarction and unstable angina pectoris (Xiang et al. 
2011). Chymase and tryptase functions (Figure 8) involved in the progression of 
atherosclerosis include lipoprotein degradation, Ang-II generation, proenzyme or 
procytokine activation, and matrix protein degradation (Xu and Shi 2012). Mast cell 
proteases are able to bind and degrade apoB in LDL leading to increased uptake of the 
modified or granule bound LDL by macrophages leading to the formation of foam cells  
(Kokkonen and Kovanen 1987, Kokkonen and Kovanen 1989). Similarly LDL particles 
coated with mast cell granule remnants coated are taken up by smooth muscle cells  
(Wang et al. 1995) thus the degranulation of mast cells plays a role in the development 
of fatty streak lesions through at least two cell types. Mast cells are not only involved in 
the generation of foam cells but also in their maintenance. Mast cell chymase is able to 
degrade lipoproteins and incubation of mouse plasma with human chymase results in 
degradation of apoA-I, apoA-II, apoA-VI, apoE and preβ-HDL resulting in the loss of the 
efflux promoting ability of mouse serum in vitro (Lee et al. 2002).  Human and rat 
chymase degrade efficiently small HDL particles at identical sites from either at the N- 
or C-terminus while larger HDL particles are less susceptible to degradation. Discoidal 
HDL particles containing apoA-II are resistant to chymase degradation whereas apoA-I 
containing particles are susceptible to degradation leading to decreased ability of these 
degraded particles to promote cholesterol efflux from cholesterol loaded foam cells.  
(Lee et al. 2003). Similarly treatment of HDL3 with either human mast cell tryptase or 
chymase causes in both cases in marked reduction in the efflux promoting ability of 
HDL3 by depletion of the minor preβ-migrating HDL subpopulation  (Lee-Rueckert and 
Kovanen 2006). 
Chymase activity is also involved in atherosclerotic plaque instability. It has been 
shown, that treatment with chymase inhibitor reduces spontaneous atherosclerosis, 
prevents accelerated plaque progression associated with systemic mast cell activation, 
reduces lesion necrotic core size and normalizes the frequency and size of intraplaque 
hemorrhages in apoE- deficient mice  (Bot et al. 2011). 
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Figure 8. Mast cell chymase and tryptase in atherosclerotic intima 
Mast cells release pre-stored mediators, such as the neutral proteases tryptase and chymase upon 
activation. The function of these proteases in the progression of atherosclerotic plaque is explained 
here in short. 1. Mast cell tryptase and chymase bind and degrade apoB in LDL. This leads to uptake of 
modified LDL by foam cells or in the aggregation and fusion of LDL on granule surface leading to 
uptake of these particles by macrophage foam cells or smooth muscle cells. 2. Tryptase and chymase 
are able to degrade HDL and structural apolipoprotein components of HDL leading to reduced 
cholesterol efflux from foam cells. 3. Chymase induces formation of angiotensin-II (Ang-II) from 
angiotensin-I (Ang-I). 4. Tryptase and Ang-II exhibit angiogenic properties. Chymase and Ang-II induce 
intraplaque hemorrhage. 5. Chymase, tryptase and Ang-II induce smooth muscle cell (SMC) apoptosis. 
6.  Chymase and Ang-II induce endothelial cell apoptosis. 7. Ang-II induce leukocyte recruitment. 8. 
Chymase and tryptase induce the production of matrix metalloproteinases (MMPs). MMPs destroy 
extracellular matrix, subendothelial collagen and basal membrane leading to detachment of 
endothelial cells. Information derived from (Ihara et al. 1999, Heikkila et al. 2008, Sun et al. 2009, 
Zhang et al. 2011, He and Shi 2013) and references mentioned in the text. 
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3.3. Mast cell function in angiogenesis and apoptosis  
Angiogenesis, the formation of new blood vessels is associated with the development 
of atherosclerotic lesions and is a key factor in plaque destabilization. Inhibitors of 
angiogenesis reduce intimal neovascularization resulting in a reduced plaque size in 
apoE–deficient mice (Moulton et al. 1999). Mast cells are found in the close vicinity of 
blood and lymphatic vessels and they release angiogenic factors including FGF2, VEGF, 
TGFβ, IL-8, histamine, heparin, and angiopoietin-1 (Maltby et al. 2009). Mast cell 
tryptase also has angiogenic properties. Tryptase directly induces proliferation of 
human dermal microvascular endothelial cells and stimulate vascular tube formation in 
vitro.  (Blair et al. 1997).  
Mast cell mediators induce programmed cell death, apoptosis. Apart from the role of 
chymase and tryptase in apoptosis (Figure 9) TNF-α is also involved in apoptosis. TNF-α 
released from mast cells triggers endothelial cell apoptosis by the translocation of 
cytochrome C from mitochondria into cytoplasm initiating a cascade leading to cell 
death  (Latti et al. 2003). Thus the degranulated mast cells may contribute to plaque 
erosion and complications of atherosclerosis.  
 
3.4. Mast cells in infarction and ischemia-reperfusion injury  
Ischemia and hypoxia induce proliferation and activation of mast cells in immature rat 
brain (Jin et al. 2009) and cardiac mast cell density increases dramatically following 
myocardial infarction (Levick et al. 2011). In a rat model, induction of cardiac infarction 
by ligation of the left anterior descending coronary artery led to a gradual increase in 
cardiac mast cells at the subepicardial site of the infarction, reaching a maximum day 
21 post infarction (Engels et al. 1995). Mast cell number increases during the healing 
process of myocardial infarction and already after 72h post ischemia mast cells 
accumulate in areas of collagen deposition. SCF expression is also increased post 
ischemia and is a potential chemotactic agent responsible for the influx of mast cells. 
(Frangogiannis et al. 1998).  Cardiac mast cells are activated and degranulate after 
myocardial ischemia releasing TNF-α among other mast cell mediators. Mast cells are 
the primary source of TNF-α after myocardial infarction and TNF-α is a possible 
mediator in the inflammatory response in the healing myocardium after ischemia-
reperfusion injury (Frangogiannis et al. 1998). Mast cell activation complicates 
ischemia-reperfusion injury. In an isolated Langendorff rat heart model mast cell 
stabilization before ischemia attenuated ischemia-reperfusion-induced mast cell 
degranulation, inhibited the release of mast cell mediators, reduced the size of 
infarction and improved myocardial contractility. Induction of complete mast cell 
degranulation before ischemia resulted in similar effects suggesting that mast cell 
mediators were at least partly responsible for conveying the harmful effects of 
ischemia-reperfusion injury.  (Jaggi et al. 2007). Inhibition of mast cell chymase alone 
also reduces myocardial infarct size, MMP-9 activation, infiltration of mast cells and 
neutrophils and inflammatory gene expression (Oyamada et al. 2011). Upon activation 
mast cells release histamine and blockage of H2R both before ischemia and during 
reperfusion reduce infarct size in a canine model (Asanuma et al. 2006). Cardiac mast 
cell-derived renin promotes local Ang-I and Ang-II formation the latter eliciting 
noradrenaline release from isolated sympathetic nerve terminals. In isolated guinea-pig 
and mouse hearts ischemia-reperfusion injury results in a significant coronary spillover 
of renin and noradrenaline accompanied by ventricular fibrillation. These effects are 
attenuated by pharmacological mast cell stabilization and in the hearts of mast cell 
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deficient mice. (Mackins et al. 2006). Mast cell-deficient mice also exhibit lower serum 
IL-6 levels indicative of cell death and less cardiac tissue necrosis after experimental 
myocardial ischemia-reperfusion injury compared to mast cell competent litter mates  
(Bhattacharya et al. 2007). 
Despite being numerically the minority of the resident and infiltrating inflammatory 
cells in the heart, mast cells are involved in numerous processes in the development of 
atherosclerosis. Different activation routes lead to mast cell degranulation and the 
release inflammatory cytokines, chemokines, proteases and other proinflammatory 
mediators affecting neighboring cells. Mast cell activation can lead to atherosclerotic 
plaque expansion and destabilization as well as maintenance of chronic inflammation. 
Mast cell stabilization and mast cell deficiency seem to be cardioprotective in 
experimental models. Mast cell stabilization or mast cell protease inhibitors could be 
potential pharmacological targets at least in controlled clinical situations such as after 
medical or surgical myocardial revascularization.  
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AIMS OF THE STUDY 
 
 
The aim of this study was to elucidate the effect of mast cell activation in the 
production of proteolytically-modified HDL and the consequences of such modification 
on cholesterol efflux from macrophage foam cells  in vivo.  
 
 
The specific aims of the study were: 
1) To investigate whether mast cell-dependent proteolysis of HDL particles would 
occur in vivo    
 
2) To clarify the role of cardiac mast cells in the production of truncated apoA and 
to identify the cleavage products of mast cell-dependent proteolysis of lipid-
free apoA-I  
 
3) To further investigate whether mast cell-dependent modification of HDL in vivo 
would alter their function in promoting cellular cholesterol efflux in vitro  and 
mRCT in vivo  
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MATERIALS AND METHODS 
 
 Methods used in publications I-IV  1.
The methods used in this study with original references are listed in Table 4. Detailed 
materials and methods are presented in the original publications.  
Table 4. Methods used in publications I-IV 
 
Method                                                                                               Original              
mo o                                                                                                               publication 
Source/ 
Reference 
Animal protocols   
Systemic mast cell activation (experimental anaphylacsis) I Kim et al. 2006 
Activation of peritoneal mast cells  II  
Isolation of peritoneal mast cells and preparation of mast 
cell lysates 
I, II, IV Lindstedt et al. 1992 
Local induction of vascular permeability in skin III  
Evans Blue Dye vascular permeability test III Manaenko et al. 2011, Radu 
and Chernoff 2013 
HDL kinetics in blood and HDL cutaneous uptake III  
Perfusion of isolated rat hearts in Langendorff apparatus IV  Langendorff 1903 
Activation of cardiac mast cells ex vivo IV  Bispo-da-Silva et al. 2010 
Functional studies in mast cells and macrophages   
Measurement of chymase activity in mouse mast cell lysates    
Measurement of chymase activity in rat mast cell granule 
remnants 
I, II 
IV 
Tchougounova et al. 2003 
Woodbury et al. 1981 
Macrophage-specific reverse cholesterol transport, in vivo 
assay  
II, III Wang and Rader 2007 
Cholesterol efflux from cultured macrophage foam cells I, II, III Lee et al. 1999 
Gene expression analysis in macrophages by quantitative 
real time reverse transcriptase polymerase chain reaction 
(qRT-PCR) 
II, III  
Degradation of lipoproteins by mast cell chymase in vitro I, II, IV  
Analysis of lipoprotein degradation products   
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE)  
I, II, IV Laemmli 1970 
Western Blotting  I, II, IV  
Two-dimensional electrophoresis II Laurell 1965 
Size exclusion chromatography (FPLC) I  
Enzyme-linked immunosorbent assay (ELISA) for mouse and 
human apoA-I 
I,II  
Mass spectrometry of apoA-I and its proteolytic fragments IV  
HDL isolation from mouse plasma II, III Lee et al. 2002 
Radioactive labeling of HDL III Bolton and Hunter 1973 
Measurement of total cholesterol, HDL, and triglycerides in 
mouse serum by enzymatic commercial kits 
II, III  
Measurement of histamine in serum, skin and buffer I, III, 
IV 
Shore et al. 1959 
Measurement of protein concentration by Lowry assay IV Lowry et al. 1951 
Histochemical staining of mast cells with toluidine blue III, IV  
Light microscopy for mast cells in skin and heart III, IV  
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2. Animals used in publications I-IV  
Animal strains and sources and project licenses are listed in Table 5.   
 
Table 5. Animals used in publications I-IV 
F, female; M, male 
 
 
3. Statistical Analysis (I-IV) 
Unpaired Student´s t-test with Welch's correction or non-parametric Mann–Whitney U 
test were used to compare data obtained from two groups. One-way ANOVA with 
Tukey's multiple comparison test, or Bonferroni's Multiple Comparison Test or a non-
parametric Kruskal-Wallis test with Dunn’s posttest were used to compare data from 
three or more groups. GraphPad Prism 4.0 software (GraphPad, San Diego, CA) was 
used for all statistical analyses. A p value <0.05 was considered statistically significant.  
 
 
 
  
Species/strain Sex Source License 
Original 
publication 
NMRI mouse F Viikki laboratory animal 
center, University of 
Helsinki 
WTL 01/2006 
ESLH-2007-05893/Ym-23 
I 
C57BL/6J   Kit
W-sh/W-sh 
mast cell deficient 
mice 
F Jackson Laboratories, 
Bar Harbor Maine, USA 
ESLH-2007-05893/Ym-23 I, II 
C57BL/6JOlaHsd 
mouse 
F Harlan Laboratories, 
Venray, Holland 
ESLH-2007-05893/Ym-23 
ESLH-2007-05892/Ym-23 
ESAVI/6461/04.10.03/2011 
ESAVI/7324/04.10.07/2013 
ESAVI/3225/04.10.07/2013 
II, III 
C57BL/6J  apoA-I 
deficient mice 
F, M Kindly provided by Dr. 
Jesús Osada, University 
of Zaragoza, Spain 
In collaboration at Sant 
Pau-CIBER de Diabetes y 
Enfermedades Metabolicas 
Asociadas, Barcelona, Spain 
III 
C57BL/6J   LDLR-KO 
mice 
F Jackson Laboratories, 
Bar Harbor Maine, USA 
In collaboration at Sant 
Pau-CIBER de Diabetes y 
Enfermedades Metabolicas 
Asociadas, Barcelona, Spain 
III 
RccHan®WIST Wistar 
rat 
F Harlan Laboratories, 
Venray, Holland 
ESAVI-2010-05448/Ym-23 IV 
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RESULTS   
 
 Chymase-dependent degradation of HDL and lipid-free apoA-I in vitro 1.
The specific expression pattern and physiological responses of mast cell proteases vary 
considerably among mammalian species and between different locations in the body  
(Pejler et al. 2007). In the present study different rodent models were used to 
investigate the potential role of mast cell chymase on HDL structure and function as 
well as cholesterol metabolism. For this purpose chymotryptic activities from different 
mast cell populations were evaluated in order to produce comparable experimental 
conditions. Chymases are able to impair the ability of HDL particles to promote cellular 
cholesterol efflux from macrophage foam cells in vitro  (Lee et al. 1999, Favari et al. 
2004) and thus the relative abilities of the various chymases to degrade HDL particles 
and inhibit their function as cholesterol acceptors was assessed first in vitro.   
 
1.1. Chymase specific activity in murine mast cells (I) 
Chymase activity was measured from mast cell lysates obtained either after sonication 
or several freeze-thaw cycles of the harvested murine or rat mast cells, respectively. 
Chymase activity was confirmed by incubating the granule remnants with specific 
chymotryptic substrates. Chymase hydrolyses the substrate and the reaction velocity 
was observed as an increase in the absorbance against time in the reaction medium. 
Mouse peritoneal mast cells exhibited a linear relation between mast cell numbers and 
chymase activity. Importantly mouse chymase remained active even in the presence of 
its natural inhibitors present in intraperitoneal fluid whilst the natural inhibitors 
present in mouse plasma were able to completely inhibit chymase activity (I, Figure 1). 
This finding indicated that mouse mast cell chymase could be functional also in vivo 
when activated in locations surrounded by extracellular fluid such as in the peritoneal 
cavity or in the skin.  
 
1.2. Degradation of HDL and lipid-free apoA-I (I, II, IV) 
HDL and its main functional component apoA-I are antiatherogenic and high serum 
HDL-cholesterol is inversely related to the risk of atherosclerosis  (Assmann and Gotto 
2004). Human chymase is known to degrade human lipid-free apoA-I (Lee-Rueckert et 
al. 2008), and both the rat and human chymase are able to degrade human apoA-I 
present in preβ-HDL-migrating reconstituted HDL particles  (Lee et al. 2000, Lee et al. 
2003, Favari et al. 2004, Usami et al. 2013).  Notably, the mature alpha-migrating HDL 
particles are poorly degraded by either the rat or human chymase, which contrasts to 
the high sensitivity of the lipid-free apoA-I and the poorly-lipidated prebeta-HDL found 
in human plasma to these proteases  (Lee et al. 1999). In the present  study HDL 
particles have been treated with mast cell proteases in vivo in the mouse, or human 
lipid-free apoA-I has been administered to mice in conditions of local mast cell 
activation. Thus, in preliminary experiments, the ability of mouse chymase to degrade 
HDL in mouse serum as well as the ability of mouse, rat, and human chymases to 
degrade human lipid-free apoA-I in vitro were assessed. For this purpose, recombinant 
human chymase  and chymase from mouse or rat origin were incubated in TNE-buffer 
with mouse serum or with lipid-free human apoA-I. Mouse serum contains > 70% of 
total cholesterol in HDL particles, the main HDL protein component being apoA-I (> 
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50% of total weight) and very little circulating lipid-free/lipid-poor apoA-I  (Camus et al. 
1983). The results revealed that mouse chymase was able to partially degrade both α- 
and preβ-HDL subtypes present in mouse serum in vitro (I, Figure 2A). Mouse chymase 
also proteolyzed, similarly to the human chymase, lipid-free human apoA-I in vitro (II, 
Figure 1). These results reveal that mouse chymase has a wider spectrum for HDL 
proteolysis than its human and rat counterparts. Importantly when either mouse 
chymase or human chymase was incubated with human lipid free apoA-I they both 
produced a similar proteolytic pattern characterized by the appearance of two major 
apoA-I fragments (II, Figure 1A) suggesting that mouse and human chymase cleave 
apoA-I in a similar manner. Further comparison between the abilities of human and rat 
chymases to degrade lipid free apoA-I however, revealed some differences. As 
mentioned, human recombinant chymase produced a proteolytic pattern characterized 
in the SDS-PAGE by two bands appearing below the band of intact apoA-I. The bands 
had apparent MW of 26kDa and 22kDa the smaller of the two growing dominant over 
time (IV, Figure 6). Rat chymase, however, produced a proteolytic pattern 
characterized  by only one band with apparent MW of 22kDa (IV, Figure 6). The amount 
of chymase or the incubation time appeared not to be limiting in the ability of chymase 
to proteolyze lipid-free apoA-I. When the incubation with recombinant chymase was 
either continued up to 24h or chymase was added after 2h to reach double the 
chymase activity, the proteolytic pattern remained essentially the same favoring the 
proteolytic product with apparent MW of 22kDa (IV, Figure 6C).  
The ApoA-I proteolytic products were further characterized by blotting the proteins 
onto nitrocellulose membrane and detected by a polyclonal apoA-I antibody and the 
16-4 mAb, which specifically reacts with truncated apoA-I at the carboxyl side of Phe225 
generated by human chymase. The human and rat chymase proteolytic products 
described above reacted with the polyclonal anti apoA-I antibody confirming them as 
apoA-I degradation products (IV, Figure 7). The 16-4mAB, however, reacted only with 
the apoA-I degradation product with apparent MW of 26kDa produced by human 
chymase (IV, Figure 7). This suggested that the minor cleavage site Phe225 was specific 
for human chymase.  
1.2.1. Identification of apoA-I cleavage sites (IV)  
ApoA-I degradation products were identified by mass spectrometry. Human chymase 
produced three C-terminally truncated polypeptides, Phe229,  Phe225 and Tyr192 with 
molecular weights of 26,458kDa, 25,964kDa and 22,395kDa, respectively (IV, Table 2). 
These fragments agreed with the carboxyl-terminally digested apoA-I degradation 
products previously reported for the human chymase (Usami et al. 2013). Rat chymase 
produced only the smallest  of the fragments, the 22,395kDa polypeptide.  
 
1.3 Ability of apoA-I to promote macrophage cholesterol efflux in vitro (II) 
In the present study mouse models were used to investigate the in vivo effects of mast 
cell activation on the ability of serum, HDL and lipid-free apoA-I to induce cholesterol 
efflux from macrophages loaded with acetylated LDL and to promote mRCT. The 
following mouse models were used in the present study: C57Bl/6J or NMRI mice fed 
with regular chow rodent diet (Teklad Global, Harlan Laboratories) with access to water 
ad libitum, maintained in an automatic 12/12 h dark-light cycle. Mice were treated with 
various doses of C48/80 or the vasoactive compounds, histamine, serotonin or 
bradykinin. Mast cell deficient, apoA-I deficient and LDLR-KO mice of C57Bl/6J 
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background were used to study the individual variables affecting the studied model. 
Thus the ability of lipid free apoA-I to act as cholesterol acceptor was first assessed in 
vitro after incubation with mouse chymase. ApoA-I was incubated in TNE-buffer with 
mouse mast cell lysate with increasing chymase activity and these chymase-treated 
preparations were then added to cell culture medium containing mouse peritoneal 
macrophage foam cells in which the ABCA1-mediated pathway is up regulated 
(Langmann et al. 1999). The ability of the chymase treated apoA-I to promote 
cholesterol efflux from cholesterol leaded macrophage foam cells was diminished to 
~20% when compared to non-treated apoA-I (II, Figure 1B). This decrease in the efflux 
capacity was seen already when apoA-I was incubated with the smallest chosen 
chymase activity, 18U,  corresponding to ~10% of the chymase activity present in the 
entire mast cell population in mouse peritoneal cavity. When more chymase was added 
to the reaction buffer the efflux capacity of apoA-I decreased to~8% with the highest 
chymase activity (144U). These results denoted that mouse chymase had functionally 
inactivated human apoA-I.   
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2. Effect of cardiac mast cell activation on apoA-I structure ex vivo (IV) 
To further study the physiological relevance of mast cell activation and the production 
of truncated, non-functional apoA-I, the ability of cardiac mast cell chymase to degrade 
apoA-I was studied.  Cardiac mast cells were studied in an isolated rat heart 
Langendorff model and mast cell degranulation was induced by perfusion of C48/80 
(300µg) or by the induction of either global or moderate ischemia (perfusion stopped 
or reduced to 10%, respectively, for 20min). Mast cell activation was followed by the 
perfusion of human lipid-free apoA-I. Hearts were harvested from adult Wistar rats, 
mounted on a Langendorff apparatus, cannulated over the aorta and perfused with  
constantly carbogen-gassed physiological buffer.  The extent of mast cell activation was 
evaluated by counting the number of resting and degranulated mast cells from heart 
sections after the induction of mast cell activation by the described treatments  (IV, 
Figure 2). Extensive mast cell activation after C48/80 treatment was confirmed by a 
significant increase in the percentage of degranulated mast cells compared to the 
control as well as an increase in histamine levels measured from the collected 
perfusion buffer (IV, Figure 3A). Global and moderate ischemia both led to non-
significant increases in the number of degranulated mast cells as well as a moderate 
increase in histamine detected in the perfusate (IV, Figure 2C-2E and Figure 3A). Global 
ischemia appeared to have a stronger tendency to stimulate mast cells.   
ApoA-I was administered to the hearts under 3 different conditions: before C48/80 
(resting mast cells), immediately after the infusion of C48/80 (activated mast cell), and 
finally immediately prior stopping the flow for 20 min (global ischemia). In separate 
experiments ischemia (global or moderate) was induced in hearts without the 
preceding treatment with C48/80 which is known to deplete the mast cells from the 
pre-stored mediators  (Jaggi et al. 2007). In hearts only subjected to ischemia apoA-I 
was infused after the induction of ischemia. ApoA-I flowed very rapidly through the 
heart indistinct peaks after the injection of apoA-I into the perfusion line (IV, Figure 
3B). Perfusate samples of the respective protein peaks containing apoA-I were analyzed 
on 4-12% Bis-Tris PAGE gels and Instant Blue detection. Perfusion of lipid-free apoA-I 
after cardiac mast cell activation by C48/80 and consequently the release of chymase 
resulted in the production of a similar proteolytic pattern as seen after the in vitro 
proteolytic degradation by human and mouse chymase (II, Figure I; and IV, Figure 4). 
The proteolytic pattern was characterized by two bands corresponding to degraded 
apoA-I fragments of apparent MW of 26 kDa and 22 kDa the latter one being markedly 
minor. Infusion of apoA-I after the induction of moderate ischemia resulted in the 
production of a single degradation product with apparent MW of 22kDa. Global 
ischemia, either with or without the preceding C48/80 treatment, did not however 
result in apoA-I proteolysis.   
The cleavage sites of apoA-I and the molecular masses of the digestion products 
generated by cardiac mast cell chymase were identified by mass spectrometry. The two 
fragments generated by C480/80 induced cardiac mast cell activation were identified as 
chymase proteolytic products cleaved at Phe229 and Tyr192 with molecular masses 
26,458 kDa and 22,395 kDa, respectively (IV, Table 1). Induction of moderate ischemia 
resulted in the production of a single band detected on the PAGE and this proteolytic 
product was identified as a chymase product cleaved at Tyr192 with a molecular mass 
22,395 kDa (IV, Table 1). Mass spectrometry analysis revealed no additional apoA-I 
degradation products in perfusates after induction of global ischemia either with or 
without prior treatment of the hearts with C48/80. The relative proportion of the 
generated apoA-I fragments were calculated by measuring the heights of the peaks in 
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the mass spectra profile in the perfusate samples collected from C48/80-treated 
hearts. The height of the full-length apoA-I was set as 1 and the peaks corresponding 
the generated apoA-I fragments were expressed relative to it (IV, Figure 5). The relative 
peak size of the 26,458 kDa fragment was 3-fold and of the 22,395 kDa fragment ~1.6-
fold while the 22,395 kDa fragment detected after induction of mast cell activation 
through moderate ischemia was clearly minor (2.4%) compared to the peak of intact 
apoA-I.  
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3. Effect of mast cell activation on HDL and apoA-I proteolysis in vivo  
 
3.1. Degradation of HDL and apoA-I (I, II)  
The effect of mast cell activation and degranulation on serum HDL was assessed in mice 
using two activation models, a systemic mast cell activation and local mast cell 
activation. Systemic mast cell activation was induced by a high dose of C48/80 
(8mg/kg) and the local mast cell activation by a low dose of C48/80 (0.5-1mg/kg) ip. 
Systemic mast cell activation was confirmed by a two fold increase in histamine 
concentration in serum and a 3-fold lower chymase activity in isolated peritoneal mast 
cells in samples derived from stimulated mice. Serum apolipoprotein profile after 
systemic mast cell activation was analyzed by applying serum total lipoprotein fraction 
on SDS-PAGE and unfractionated serum on SDS-PAGE followed by western blotting. 
The major apoA-I band, and the minor apoE and apoA-IV protein components were 
reduced and the serum contained less of both α- and preβ-HDL particles in mice after 
systemic mast cell activation (I, Figure 3).  In mouse serum the majority of cholesterol 
and phospholipids are present in HDL. Mouse lipoprotein profile was thus analyzed by 
FPLC size exclusion chromatography and the fractions for cholesterol, phospholipids 
and apoA-I were determined (I, Figure 4A). HDL in each apoA-I, total cholesterol and 
phospholipids was reduced in mouse serum following systemic mast cell activation. 
Cholesterol and phospholipids present in apoB-containing lipoproteins, however,   
remained unchanged suggesting that HDL was the chymase target amongst the 
lipoproteins in mouse serum. Thus systemic mast cell stimulation resulted not only in 
quantitative reduction of HDL components, but also in altered lipid composition.  
The effect of local peritoneal mast cell activation on exogenous lipid-free human apoA-I 
injected to the peritoneal cavity was assessed in mice. After mast cell activation 
peritoneal fluid was collected and its apoA-I concentration was determined by ELISA. 
Human apoA-I rapidly decayed after local mast cell activation reflected by a decrease in 
apoA-I concentration and the reduction in preβ-HDL, neither of which was observed in 
sham treated mice (II, Figure 5).   
3.1.1. Effect of in vivo mast cell activation on the cholesterol acceptor function of 
mouse serum, intraperitoneal fluid and apoA-I in vitro (I, II)  
Effect of systemic or local mast cell activation on the ability of mouse 
serum/intraperitoneal fluid or apoA-I, respectively, to promote cellular cholesterol 
efflux in vitro was assessed. To induce systemic mast cell activation, a high dose of mast 
cell degranulating compound C48/80 (8mg/kg) was given to mast cell competent NMRI 
mice and mast cell-deficient W-sash c-kit mutant mice. Serum and peritoneal fluid from 
treated and non-treated control mice were collected and cellular cholesterol efflux to 
serum and peritoneal fluid were determined (I, Figure 5). Systemic mast cell activation 
in mast cell competent mice significantly reduced the ability of serum and peritoneal 
fluid to promote cholesterol efflux. Treatment of C48/80 given to mast cell deficient 
mice did not however alter the ability of serum or peritoneal fluid to promote 
cholesterol efflux. This provided strong evidence that the inhibitory effect on efflux in 
the mast cell-competent mice was due to acute systemic mast cell activation and that 
proteolytic inactivation of HDL by mast cell chymase had occurred in mast cell-
competent mice during the mast cell activation in vivo. Similarly when mice were given 
intraperitoneal injection of human lipid-free apoA-I with a simultaneous induction of 
local peritoneal mast cells activation, the ability of peritoneal fluid containing apoA-I to 
promote cellular cholesterol efflux from mouse macrophage foam cells in vitro was 
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decreased (II, Figure 2). Such inhibitory effect on cholesterol efflux was dose-
dependent and a lower dose of C48/80 (0.5mg/kg) had a significant but less marked 
effect on cholesterol efflux than the higher dose (1mg/kg).  This suggests that higher 
dose of C48/80 induces a vaster mast cell activation leading to more efficient 
degradation of cholesterol acceptors present in peritoneal fluid finally resulting in 
retarded  macrophage cholesterol efflux in vitro. The effects of the different treatments 
on cholesterol acceptors and their ability to promote cellular cholesterol efflux are 
summarized in Table 6.   
Table 6. Summary on the ability of in vivo modified cholesterol acceptors to promote cholesterol 
efflux in vitro  
 
 
 
 
 
 
 
 
 
 
↑= increase efflux, ↓= decrease, ↔ = no effect compared to control animals, - = not determined 
The ability of serum and intraperitoneal fluid (IPF) to promote cholesterol efflux from cholesterol 
loaded mouse macrophage foam cells in vitro was evaluated. Serum and/or intraperitoneal fluid was 
collected from mice treated with C48/80 (8mg/kg, sc systemic activation or 1mg/kg, ip local 
activation) or from non-treated animals and was added to the efflux medium (final concentration of 
serum/IPF in medium 2.5%). Mice with local mast cell activation received apolipoprotein (apoA-1) or 
vehicle intraperitoneally. MC
+/+
, treatments to mast cell competent mice; MC
-/-
, treatments to mast 
cell deficient sash mice.  
 
3.2. Local mast cell activation and macrophage reverse cholesterol transport (II, III) 
Reverse cholesterol transport is the mechanism for removal of intracellular cholesterol 
from peripheral tissues to final excretion to feces (van der Velde 2010, Annema and 
Tietge 2012, Lee-Rueckert et al. 2013). In the present study the effect of local mast cell 
activation on mRCT was studied. Local mast cell activation was induced either in the 
peritoneal cavity (C48/80 1mg/kg, ip) or dorsal skin (C48/80 2.5mg/kg, sc) of mice and 
the rate of mRCT was determined in the presence of either exogenous human lipid-free 
apoA-I (peritoneal cavity) or  endogenous cholesterol acceptors (skin). To study the in 
vivo effect of local mast cell activation in peritoneal cavity on the rate of RCT, the 
established macrophage-specific 48h RCT assay (Zhang et al. 2003) was modified to a 
3h RCT model. The study  was designed to evaluate mRCT in model in which mast cells 
are acutely triggered to activate with a proceeding single dose of human apoA-I. Since 
apoA-I is metabolized relatively rapidly (II, Figure 5), the reliability of the RCT assay was 
evaluated in a setting in which the time between the intraperitoneal injection of 
labeled macrophages and the collection of samples was shortened to 3. 
Traditionally in RCT model mice are given [3H]cholesterol-loaded macrophage foam cell 
and the appearance of [3H]cholesterol tracer is detected from serum and fecal content 
either at 24 or 48h  (Escola-Gil et al. 2009, Rader et al. 2009). In the present study, 
however, already after 3h detectable amount of [3H]cholesterol tracer could be 
detected in serum and intestinal content (II, Supplemental Figure 1) and activation of 
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liver X receptor was able to significantly increase the passage of labeled cholesterol 
from intraperitoneally injected J774 macrophage foam cells to intestinal content in the 
measured 3 hour period (II, Supplemental Figure II). RCT was thus evaluated in a 3 hour 
period in vehicle (non-stimulated) or C48/80 (stimulated) treated mice receiving 
consecutive intraperitoneal injection of human apoA-I (3 mg/kg). Three hours after the 
injection of macrophages, blood, liver, and total intestinal lumen contents were 
collected and the [3H] tracer radioactivity was measured from the samples (II, Figure 
3). The levels of [3H]cholesterol in plasma were reduced both in the non-stimulated 
and in the stimulated group but more importantly, the [3H]tracer in intestinal lumen 
contents was significantly higher in the non-stimulated mice than in the stimulated 
mice receiving apoA-I (II, Figure 3C). This demonstrates that the intraperitoneally 
injected human apoA-I increases the transfer of macrophage-derived cholesterol to the 
intestinal lumen and mast cell activation is able to completely block such stimulatory 
effect. Moreover, it was found that C48/80 increased the level of mRNA expression of 
ABCA1 (but not of ABCG1 or SR-BI) in cultured J774 macrophages (II, Supplemental 
Figure III) suggesting that observed inhibitory effect of C48/80-treatment on RCT was 
not due to inhibition cellular cholesterol transporters but rather to inhibition of the 
ligand of ABCA-1 transporter, apoA-I. To further prove that the above results were due 
to mast cell activation and degranulation the described RCT experiment was repeated 
in mast cell deficient W-sash c-kit mutant mice.  In contrast to the results of mast cell 
competent mice, the [3H]tracer levels of mast cell deficient mice were significantly 
increased in the intestinal lumen in both stimulated and non-stimulated groups relative 
to the control group (II, Figure 3F), indicating that the compromised RCT rate in the 
C48/80-treated wild-type mice was mast cell dependent. 
Mast cell chymase inhibitory effect on the ability of apoA-I to promote mRCT was 
validated using two further experimental setups. First apoA-I was pretreated with 
isolated mouse mast cell granules as previously described in section 1.2. Such 
pretreated apoA-I was then injected to the peritoneal cavity of wild type mice together 
with cholesterol loaded macrophage foam cells and the appearance of the [3H] tracer 
was evaluated in intestinal content after 3 hours. [3H]tracer levels were significantly 
lower in mice receiving the pretreated apoA-I compared to mice receiving intact apoA-I 
thus demonstrating that indeed, the chymase degraded apoA-I was unable to promote 
RCT (II, Figure 4).  Secondly wild type mice were treated with phosphatidylcholine as 
small unilamellar vesicles (SUV) which efficiently induce aqueous diffusion of cellular 
unesterified cholesterol (Dass and Jessup 2000) and are not susceptible to adverse 
modification by chymase. Mice received SUV intraperitoneally together with C48/80 or 
vehicle alone, another group of mice received C48/80 alone. Three hour RCT was then 
assessed in these treated mice and the appearance of [3H] tracer measured in 
intestinal content. SUV (30 mg/kg) significantly increased the transfer of [3H] 
cholesterol from foam cells to intestine, and importantly, activation of peritoneal mast 
cells failed to alter the rate of RCT (II, Figure 4).  In this experimental set up the effect of 
C48/80 (1 mg/kg) alone without the stimulatory effect of exogenous apoA-I failed to 
affect the overall RCT. C48/80 alone was unable to alter the basal RCT originating from 
intra peritoneally injected macrophage foam cells (II, Figure 4).  
Local mast cell activation and its effect on RCT originating from the skin of wild type 
mice was assessed. Mast cells in the skin were stimulated to degranulate by sub 
cutaneous injection of C48/80 (2.5 mg/kg). Injection of C48/80 was accompanied by 
the injection of J774 foam cells and RCT was evaluated in 48h. Injection of C48/80 
induced local mast cell degranulation in the skin, demonstrated by increased number of 
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degranulated mast cells at the injection site and confirmed by a significant reduction in 
the histamine content of the injected skin site 1 hour after the injection of C48/80 (III, 
Figure 8A). Interestingly local mast cell activation in the skin did not decrease RCT as 
was expected based on the proteolytic effect demonstrated earlier (I, II) but in contrast  
induced significant increase in the transfer of [3H]cholesterol derived from macrophage 
foam cell to feces in 48h (III, Figure 8B).  Treatment with C48/80 did not modify serum 
lipids in mice (III, Table 5), nor effect the efflux capacity of mouse serum to induce 
macrophage cholesterol efflux in vitro when C48/80 was added to culture medium (III, 
Figure 8B inset). Mast cell activation is known to induce the release of not only the 
natural proteases but also a selection of inflammatory mediators capable of increasing 
vascular permeability such as histamine, serotonin and bradykinin among others 
(Kunder et al. 2011).  Increase in vascular permeability could in normolipemic mice, in 
which majority of cholesterol is present in HDL, induce influx of HDL cholesterol to the 
site of increased permeability. Increased local availability of HDL at the skin site of 
macrophage injection can increase cholesterol efflux from macrophage foam cells and 
this could potentially explain this apparently paradoxical antiatherogenic effect of mast 
cell activation in this experimental set up. Summary of the effects of local mast cell 
activation on RCT is portrayed in Table 7.  
 
Table 7. Summary of the effects of mast cell activation on mRCT in vivo  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
↑= increase RCT, ↔ = no effect compared to vehicle treated animals, - = not determined 
Macrophage-specific reverse cholesterol transport (mRCT) was evaluated in mice after local mast cell 
activation by C48/80 (1 mg/kg, ip or 2.5 mg/kg, sc). RCT in 3 hours was measured in mast cell 
competent (MC
 +/+
) or mast cell deficient (MC
-/-
) mice from peritoneal cavity to intestinal content after 
mast cell activation and treatment with apoA-1, 3mg/kg, ip. Other mice received phosphatidyl choline 
as small unilamellar vesicles (SUV, 30mg/kg) with or without mast cell activation or chymase-
pretreated apoA-I (pr-apoA-I) without mast cell activation. RCT in 48 hours was measured from skin to 
feces after mast cell activation.   
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4. Effect of increased local vascular permeability on macrophage reverse 
cholesterol transport in vivo  
Since mast cell activation in skin was able to promote mRCT the possible effect of 
different mast cell-derived inflammatory mediators alone to induce HDL influx to skin 
and thus the ability to promote mRCT was studied. Murine mast cells release 
histamine, bradykinin and serotonin among others upon activation (Theoharides et al. 
2012) and their involvement in vascular permeability, local HDL influx to skin and RCT 
was evaluated.   
 
4.1. Vasoactive inflammatory mediators induce HDL influx to the skin (III) 
Increased RCT from skin to feces observed after mast cell activation was hypothesized 
to be due to increased vascular permeability and consequently increased influx of HDL 
to the skin site. To mimic this, mice were given sub cutaneous injections of histamine 
(250µg/kg sc) 30 min after administration of Evans Blue dye (2% in NaCl; 4 ml/kg) and 
the appearance of the dye at the injection site was evaluated. Within 10min of the 
histamine injection a local permeability reaction was seen at the injection site reflected 
by the appearance of a blue-colored area in the skin (16±2.4 mm at 10min and 18±3.3 
mm at 30min) whereas injection of vehicle alone to skin was without effect. One hour 
after the histamine injection the histamine contents in the treated skin were similar in 
histamine-treated and vehicle-treated mice (0.39±0.02 and 0.38±0.04 ng/mg of skin, 
respectively; n=6 mice/group), reflecting the short half-life of histamine and its rapid 
clearance (Laroche et al. 1991).  
In normal conditions the blood endothelium is highly impermeable to molecules larger 
than ∼ 3 nm but acute changes in vascular permeability result in loss of 
transendothelial resistance leading to opening of endothelial gaps resulting in loss of 
fluid and plasma proteins from the intravascular space into the interstitial space 
(Breslin 2011, Kunder et al. 2011).  Thus the influx of serum HDL to skin after induction 
increased local permeability by the injection of histamine, serotonin or bradykinin was 
evaluated. To test this, mouse HDL was isolated from normal wild type mice, 
radiolabeled in its protein component, and injected intravenously to lateral tail vein 
immediately after the mice had received sc. injection of histamine (250µg/kg), 
serotonin (500µg/kg) or bradykinin (500µg/kg). After 1h and 24h, mice were sacrificed 
and the skin sites into which the vasoactive compound had been injected were 
collected and their HDL contents were measured. After histamine treatment the skin 
HDL content was also measured at time 48h. Local increased permeability in skin 
capillaries led to significant increases in skin HDL content 1h after histamine, serotonin 
or bradykinin injection whereas after 24h skin HDL content had declined to the level of 
vehicle treated mice (III, Figure 3B; and Figure 4A). No further changes in skin HDL 
content was observed at 48h after histamine treatment (III, Figure 3B). The local effect 
on permeability induced by sc. injection of histamine, serotonin or bradykinin did not 
modify the clearance kinetics of the circulating pool of HDL (III, Figure 3A; and Figure 4A 
inset). It was thus feasible that the increased influx of HDL to skin could promote RCT 
from skin to feces.  
4.2. Increased influx of HDL to skin enhances macrophage reverse cholesterol transport 
(III) 
The ability of inflammatory mediators to alter macrophage-derived mRCT from skin to 
feces in 48h was measured. Histamine, serotonin and bradykinin were tested in 
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separate experiments. Cholesterol-labeled macrophages were injected to the sub 
cutaneous layer of the skin immediately prior to injection of histamine. Mice received a 
second sc. dose of histamine 24 h after the first dose to repeat the short and transient 
histamine effect.  After 48 h of injection of the cells, the transfer of macrophage-
derived [3H] cholesterol to feces was evaluated. Similarly as after local mast cell 
activation in the skin, injections of histamine to the skin were able to promote mRCT 
from skin to feces (III, Figure 1). Histamine conveys most of its effects in vasculature 
through H1R and/orH2R (Ma and Kovanen 1997) and thus their effect in the studied 
model was evaluated. For this, 1h prior histamine injection, mice received 
intraperitoneal injections of either H1R or H2R antagonist (pyrilamine 20mg/kg or 
ranitidine 20mg/kg respectively) or both antagonist together and the fecal recovery of 
the macrophage-derived [3H]-radioactivity was measured (III, Figure 2). The 
stimulatory effect of histamine on the mRCT was significantly reduced when the H1R 
antagonist was administered, and only slightly reduced when the H2R antagonist was 
administered. When the two antagonists were administered together, they exhibited a 
slightly stronger inhibitory effect than H1R antagonist alone, suggesting that the H2R 
antagonist had a small additive effect in combination with the H1 antagonist. The 
histamine effect on mRCT appeared thus to be mainly H1R mediated. 
The effect of serotonin and bradykinin on RCT from skin to feces was evaluated in a 
similar experiment. Mice were given either serotonin or bradykinin subcutaneously 
(500 µg/kg, each) immediately after injection of the cholesterol-labeled macrophages 
and the transfer of the [3H]tracer from skin to feces was determined after 48h. Mice 
received an additional injection of either of the compounds 24h after the injection of 
the cells. Both serotonin and bradykinin were able promote significant increases in 
fecal excretion of [3H]cholesterol and the  [3H]tracer in bile acid fraction in feces  thus 
leading to significantly increased recovery of the[3H]tracer in total feces (III, Figure 4). 
None of the studied compounds affected serum HDL levels, cholesterol transporter 
gene expression or cholesterol efflux induced by serum from cultured J774 
macrophages (III, Figure 5; Tables 1 and 2).  
To further prove that the observed increase in mRCT was due to increased influx of HDL 
to skin, a similar experiment was repeated in mice with naturally occurring low serum 
HDL. ApoA-I deficient mice exhibit ~2-fold lower levels of HDL-cholesterol relative to 
the wild-type mice (III, Table 3). The apoA-I deficient mice were injected with histamine 
as described above. Histamine was administered twice, 24 h apart, and feces were 
collected over 48 h. Histamine injection to apoA-I deficient mice was unable to affect 
the overall mRCT from skin to feces (III, Figure 6). Similarly when HDL was intravenously 
administered to the lateral tail vein of the apoA-I deficient mice the mRCT remained 
unaffected. Importantly, when  HDL was administered to apoA-I deficient mice 
together with histamine as described above, the ability of histamine to increase mRCT 
from skin to feces was recovered.  Together this data demonstrate that the 
inflammatory mediators released by mast cells can each individually increase RCT 
originating from macrophage foam cells in the skin simply by increasing vascular 
permeability leading to HDL influx to skin. 
To further test this hypothesis, the effect of histamine on mRCT was evaluated in the 
atherosclerosis-prone LDLr-KO mice, having normal HDL levels but 10-fold higher levels 
of apoB-containing lipoproteins compared to the wild-type (III, Table 4). Histamine 
treatment in these hypercholesterolemic mice was unable to promote mRCT (III, Figure 
7). Interestingly, the basal rate of mRCT appeared to be increased in LDLr-KO mice 
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(0.45% of injected dose) (III, Figure 7C) compared to the wild-type mice (0.11%, in III; 
Figure 1C, and 0.10% in III; Figures 4B and 4C). It may well be, that histamine and as 
well as hypercholesterolemia induce vascular leakage (Phinikaridou et al. 2013) and 
thus histamine effect becomes shunted in LDLr-KO mice. (22, 23). 
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DISCUSSION 
1. Methodological considerations 
 
1.1. Animal models 
In this study mice were used to study whether the rate of reverse cholesterol transport 
that originates in macrophage foam cells, the pathway which protects from the 
development of atherosclerosis, may be affected by biologically active mediators 
released from mast cells.  Animal models can be used to study human physiology, 
pathophysiology, and metabolism when the differences between the chosen animal 
species and humans are kept in mind and there are no direct assumptions from animal 
studies to human physiology. Importantly, considering the present study, there is a 
high homology between mouse and human apoA-I  (Collet et al. 1997). However, mice 
and humans exhibit one pronounced difference in the RCT pathway. In humans as well 
as in rabbits and hamsters but not in mice and rats CETP is able to remove cholesterol 
from α-HDL to apoB-containing lipoproteins thus allowing the hepatic LDLRs to take 
part in RCT between the forward and the reverse cholesterol transport  (Annema and 
Tietge 2012). Also although no inbred strains of mice develop spontaneous complex 
atherosclerotic lesions, mice are nevertheless a good surrogate to study the basic 
physiological responses to certain stimuli. Mice are easy to manipulate and their 
housing and maintenance is relatively inexpensive compared to the true 
“atherosclerotic” animals such as pigs and non-human primates. Even though wild type 
mice do not produce spontaneous atherosclerosis, they can develop early microscopic 
fatty streak-type lesions when fed a diet enriched in both cholesterol and fat (Whitman 
2004). Of the most commonly used inbred mouse strains, the C57BL/6 strain is most 
susceptible to the formation of early atherosclerotic lesions (Paigen et al. 1990). 
C57BL/6 mice fed an atherogenic diet have lower serum HDL levels compared to 
littermates on a normal chow diet. Males and females of this strain on normal chow 
have similar serum HDL-lipid, but females have a 50% decrease in serum HDL when fed 
an atherogenic diet. In these mice low serum HDL levels correlate to the development 
of atherosclerotic lesions. (Paigen et al. 1987). Based on this “strain-specific” 
susceptibility to atherosclerosis, C57BL/6 is the most commonly used strain to study 
atherosclerosis, including studies using genetically modified mice  (Whitman 2004).  
In the present study NMRI mice were first chosen to investigate the effect of systemic 
mast cell activation. Unlike C57BL/6 mice, NMRI strain is an outbred strain, ie. the mice 
are not bred from generations of brother-sister matings but rather from a rotational 
breeding system  (Nomura and Yonezawa 1996) which makes it possible to maintain a 
high genetic heterogeneity while keeping a closed population. Outbred stocks of mice 
are widely used in toxicology, pharmacology and fundamental biomedical research. 
Some researchers believe, however, that the use of outbred mice results in larger study 
groups compared to studies using inbred mouse strains. The more labile genetic 
background leads to more variation in response to treatments which leads to 
unnecessary repeats of the experiment. (Chia et al. 2005). In the present study NMRI 
strain was chosen originally for cell isolations and for such use this strain is optimal due 
to the larger size and easy manipulation. NMRI mouse strain was also used to study 
systemic mast cell activation and in the present study the sizes of the study groups 
remained feasible. In the same experimental setup mast cell deficient mice of C57BL/6 
background were also used and in groups using these mice, the variation was indeed 
less marked and the groups remained somewhat smaller. Comparing the results 
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obtained from studies using an inbred and outbred mouse strain can prove 
problematic. In the present study matched control groups from within the mouse strain 
were used and the two strains were not compared to each other. In other experimental 
setups C57BL/6 mouse strain was chosen to investigate the local mast cell activation 
and its effect on cholesterol metabolism. Female C57BL/6 mice were chosen for the 
experimental animals for reasons discussed above. In addition, the two most 
commonly used mouse atherosclerosis models, the apoe−/− and ldlr−/− mice, which 
develop spontaneous or diet-induced atherosclerotic lesions, are of C57BL/6 
background (Whitman 2004). Indeed in study III apoA-I deficient mice as well as LDLr-
KO of C57BL/6 background were used. Also if the present studies are to be expanded in 
more “human-like” atherosclerotic models these two single gene deletion models 
would provide a suitable design and thus the basic studies should be carried out in 
mice with a similar background.  
For the isolated heart model the  rat was chosen as the preferred rodent model. The 
small size of the mouse heart represents a practical challenge using the Langendorff 
heart model and thus the bigger of the two most commonly used rodent models, the 
rat, was chosen for this study. Wistar is an outbred rat strain and as discussed above 
the use of such strains has its limitations. In the present study however, Wistar rats 
were only used for the isolation of the hearts and no treatments were performed on 
the living animal. In such experimental setup the use of an outbred strain is acceptable 
since the variation between animals on basic anatomical structures is insignificant. 
Wistar rats, when fed an atherogenic diet, develop a serum lipid profile resembling that 
of hyperlipidemia in humans, characterized by an increase in serum LDL and total 
cholesterol levels as well as a decrease in serum HDL levels (Zulet et al. 1999). 
Moreover, adding a thyroid hormone inhibitor to the atherosclerotic diet results in the 
formation of atherosclerotic lesions  (Joris et al. 1983). The Wistar rat is thus used as a 
model of the development of spontaneous experimental atherosclerosis.   
 
1.1.1 Ethics of animal use 
Ethics of animal use is a complex and multifaceted subject and it will be discussed here 
only shortly in relation to the present study.  
Mouse is the most commonly used laboratory animal in Europe and in Finland  (EU 
2013, ESAVI 2014). In Finland 6979 mice and 1798 rats were used for cardiovascular 
research, with the total animal number including all species being 9153 in the year 
2013 (ESAVI 2014). At the EU level the numbers are 373 188 and 118 849 for mice and 
rats respectively  (EU 2013). The basic studies and advances in the biomedical sciences 
depend critically on the use of animals as models of human physiology, 
pathophysiology, and metabolism. Laboratory mice can be kept in large colonies, 
experiments can be carried out systematically and with only a few variables and the 
use of mice has one advantage that simply cannot be emulated in human subjects, the 
manipulation of murine stem cells and the ability to create knockout and transgenic 
mouse strains. This allows the study of single gene-mutations and a deeper 
understanding of disease pathways.  (Russell 2003).  
In the present study mice and rats were used for three types of experimentation, in 
vitro experiments using animal serum, tissues or cells collected from euthanized 
animals, ex vivo experiments using rat hearts for functional studies and in vivo 
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experiments using mice for  mRCT studies. The preliminary studies, when possible were 
carried out using in vitro cell studies but the use of laboratory animals in vivo could not 
be avoided in this study. To investigate an entire organ like the heart or to study the 
reverse cholesterol transport in a living organism, proves impossible by the use of mere 
cell cultures. When laboratory animals are chosen for a scientific protocol the wellbeing 
of the animals should be considered carefully. This increase of well-being is often 
referred to as applying the 3Rs first introduced by Russell and Burch in 'The principles 
of humane experimental technique' (1959). According to the 3Rs scientists should 
when making a study plan try to replace the animal work with alternative in vitro 
methods, reduce the number of animals used and refine routines and housing to 
achieve maximal wellbeing. All of the above have been implemented in the present 
study. In the present study inhalation anesthesia was introduced for all procedures 
(also to some injections) thus avoiding stress and misinjections of substances leading to 
unnecessary repetition of experiments and euthanasia methods were refined by giving 
up the use of carbon monoxide to be replaced by inhalation anesthesia. Also 
environmental enrichment whenever possible has been implemented. None of this, 
however means anything in the animal rights view. In the animal rights view no benefit 
can justify the violation of the rights of an individual animal (Sandøe and Christiansen 
2008). In a way it doesn't matter, and it is even pointless to consider, the possible 
benefits of the experiments for humans or for the scientific community because it is 
clear that the animals used in these experiments will only be treated as a means to an 
end and this is always considered unacceptable in the animal rights point of view. 
Scientists using laboratory animals must therefore take another more utilitarian view 
to this matter. A utilitarian would be concerned about the interests of all sentient 
beings affected by the actions of the individual (Sandøe and Christiansen 2008). The 
purpose of animal experiments, in this study, is to obtain knowledge of a possibly lethal 
disease by sacrificing animals. In the utilitarian view it is vital to find a balance between 
the costs (animal suffering) and benefit (human wellbeing). It is not only relevant what 
is right or wrong but also what could be done better. Thus it is of utmost importance to 
implement the 3Rs, maintain a high level of transparency in studies including 
laboratory animals and to keep going a continuous discussion between the scientific 
community and the public. 
 
1.2. Cell cultures and chosen cell models  
In the present study isolated mouse macrophages were used in all of the in vitro 
cholesterol efflux experiments excluding the experiments specifically targeting the 
cholesterol efflux capacity of J774 cells. Peritoneal macrophages (other than J774) were 
isolated from wild type mice always using the same strain and supplier as for the in vivo 
work. To avoid variation in the cell populations, macrophages were always freshly 
isolated from female mice of age 8-12 weeks. Prior to the efflux experiment the cells 
were maintained for 2 hours before loading the cells and this procedure was applied to 
all experiment. The cholesterol efflux protocol from macrophages is well established 
(Lee et al. 1999, Asztalos et al. 2005, de la Llera-Moya et al. 2010).  When the isolated 
macrophages are incubated with a medium including acetylated LDL the mRNA and 
protein expression of ABCA1 is up regulated  (Langmann et al. 1999). This serves an 
ideal milieu to study cholesterol efflux to apoA-I/preβ-migrating HDL which both are 
active acceptors of cholesterol from ABCA1  (Yancey et al. 2003).  
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J774 macrophage-like cell line is a commercial cell line originally isolated from BALB/c 
mouse reticulum cell sarcoma. J774 cells are widely used as model systems in cell 
biology and immunology (Lam et al. 2009) as well as in RCT studies in which J774 are 
used in most published papers  (Rocco et al. 2011, Annema and Tietge 2012, de Beer et 
al. 2013).  Use of such macrophage like cells is, however, not optimal. The cells come 
from a different strain of mice as used in the present study and the cells do not 
represent normal macrophage population but rather of tumor origin. Whether 
injection of such fully exogenous cells results in changes in the recipient tissue (eg. 
infiltration of inflammatory cells) has not been taken into account in this study.  An 
interesting methodological study would be to compare the mRCT capacities of different 
macrophage population either isolated from same strain of mice from different tissues 
(bone marrow, peritoneal cavity) or to use commercial cell lines and to see whether 
inflammatory markers are affected or whether the efflux and mRCT would differ. J774 
cells were nevertheless chosen for this study for practical reasons. In order to follow 
the [3H]tracer within the different body compartments the number of cells must be 
high and cells must be loaded with rather high concentration of the tracer and 
acetylated LDL. The latter tends to, according to our own observations, lead to some 
degree of cell death. To avoid this we used J774 cells to increases the viability of the 
cell cultures. Secondly the use of isolated mouse macrophages would increase the 
number of used animals. For these reasons J774 cells were chosen as the cell model for 
RCT experiments.  
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2. Main findings  
 
2.1. Effect of mast cell activation on the structure of mouse serum HDL and lipid-free 
apoA-I 
In atherosclerotic lesions, accumulated cholesterol is removed from foam cells via the 
ABCA1 cholesterol transporter to lipid-poor preβ-migrating HDL, which contain one or 
more copies of apoA-I. Lipid-poor HDL and apoA-I are susceptible to proteolytic 
modification compromising the various cardioprotective functions of HDL (Lee-
Rueckert and Kovanen 2011). Human mast cell chymase is able to cleave apoA-I in vitro 
in reconstituted HDL at the N-terminus (Tyr18 or Phe33) or C-terminus (Phe225) (Lee et 
al. 2003) and in the lipid-free form at C-terminus (Phe229 and Tyr192) (Usami et al. 2013). 
Changes in apoA-I structure can affect the functional domains of the protein such as 
the carboxyl-terminal, which determines the lipid binding property of apoA-I (Koyama 
et al. 2009, Lund-Katz and Phillips 2010). The C-terminus of apoA-I protein appears to 
be essential for ABCA1 mediated cholesterol efflux  (Kono et al. 2010) and specifically 
the Tyr192 in the C-terminus defines the cholesterol efflux capacity of apoA-I  (Shao et 
al. 2005). Similarly it has been shown that the C-terminus is essential for some of the 
anti-inflammatory functions of apoA-I. ApoA-I is able to bind bacterial 
lipopolysaccharide (LPS) and to protect against LPS mediated inflammatory responses 
(Ma et al. 2004). It has been demonstrated that the C-terminal part of apoA-I consisting 
of residues 149-243 generated by apoA-I decomposition  (Henning et al. 2011) or 
specific residues within the 218-222 region of the C-terminus (Biedzka-Sarek et al. 
2011) are involved in the binding with LPS. Thus it was of utmost interest to determine 
the susceptibility of the different HDL subpopulations to proteolytic modification.  
Systemic mast cell activation by C48/80 in mice led to extensive degradation of serum 
cholesterol acceptors and changes in the lipoprotein composition. The structural 
components of HDL (apoA-I, apoE and apoA-IV) were reduced and serum contained 
less of both α- and preβ-HDL. Similarly apoA-I levels in serum of C48/80 treated mice 
were lower than in the control mice. Systemic mast cell activation leads to the release 
of several inflammatory mediators such as histamine, serotonin and leukotrienes, 
which are capable of increasing vascular permeability  (Ramos et al. 1992).  Similarly 
mast cell protease tryptase is able to disrupt the barrier function of endothelial cells 
(Sendo et al. 2003) and chymase potentiates histamine-induced effect on vascular 
permeability (Rubinstein et al. 1990). Such increase in vascular permeability results in 
the leakage of fluid and plasma components with a radius of up to 22nm into the 
interstitial fluid (Rutledge et al. 1995). This would lead to the influx of serum HDL 
particles to interstial fluid already housing approximately 50% of the entire apoA-I 
content of the body (Randolph and Miller 2014). Such extravascular environment rich 
in lipoprotein substrates would be optimal for chymase proteolytic activity. Chymase, 
as also shown in this study is inhibited by natural inhibitors present in plasma. In 
interstitial fluid, however, chymase remained functional despite of the drop of activity 
to 40% in the presence of 80% of intraperitoneal fluid in the reaction assay buffer.  
Thus the degraded lipoprotein profile demonstrated in this study is a combination of 
the residing lipoproteins within the interstitial fluid and those influxed from plasma 
compartment to interstitial fluid to be degraded by the exocytosed chymase remaining 
heparin-bound and unable to leave the tissue  (Metcalfe et al. 1997).  
In atherosclerosis mast cells are “chronically” activated in the atherosclerotic intima 
(Kaartinen et al. 1994B) and systemic mast cell activation offers only an extreme model 
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to study mast cell activation and its involvement in proteolytic modification of serum 
lipoproteins. Local mast cell activation in the heart and in the peritoneal cavity offered 
a more refined environment to study lipoprotein proteolysis. Mast cells were induced 
to degranulate by C48/80 or by ischemia and the tissues were supplemented with lipid-
free human apoA-I in contrast to the described systemic mast cell activation model in 
which the substrate was endogenous mouse HDL present in serum. Both mouse 
peritoneal mast cell chymase and rat cardiac mast cell chymase were able to cleave 
lipid-free apoA-I. Degradation products appeared immediately both ex vivo and in vitro 
indicating an efficient substrate-enzyme activity. The proteolytic products were 
identified by mass spectrometry and in the present study it was demonstrated that 
human chymase in vitro produced a proteolytic pattern identical to previous reports 
(Phe229, Phe225 and Tyr192, molecular masses 26,46kDa, 25,96kDa and 22,36kDa, 
respectively) (Usami et al. 2013).  Rat chymase in vitro, was only able to produce a 
single truncation on apoA-I (Tyr192, molecular mass 22kDa). In the ex vivo model, 
however, cardiac mast cell activation by C48/80 led to the production of two C-
terminally truncated apoA-I fragments (Phe229 and Tyr192). Since the latter was the only 
fragment generated by rat chymase in vitro, it is feasible that apoA-I conformation may 
have changed during the perfusion through the rat heart. This may be explained by the 
rapid acquisition of lipids upon interaction of the perfused lipid-free apoA-I with native 
lipid structures of the intact heart, such as cell membranes. Also since the chymase 
used in the in vitro studies was isolated from peritoneal cavities of rats, the different 
mast cell populations found in peritoneum and the heart may translate to differing 
substrate affinities of chymase in these mast cell populations.  Induction of moderate 
cardiac ischemia resulted in the production of only the shorter of the fragments (Tyr192) 
while global ischemia produced none. These different proteolytic patterns observed 
after the induction of mast cell activation by either moderate ischemia or after 
treatment of C48/80 could reflect the lower degree of mast cell activation detected as 
fewer degranulated mast cells in tissue sections as well as a lesser degree of histamine 
release in the moderate ischemia setting compared to C48/80 treated hearts.  
ApoA-I degradation in mouse peritoneal cavity was determined by ELISA and detected 
as a reduction of apoA-I concentration in the peritoneal fluid collected from C48/80 
compared to vehicle treated mice. The loss of apoA-I in C48/80 treated mice was 
closely reflected by the reduction in pre-β-HDL particles, as evaluated by 2-dimensional 
immunoelectrophoresis. Despite the prominent reduction in apoA-I concentration no 
degradation fragments were found in the peritoneal fluid. When apoA-I in this study 
was incubated with mouse peritoneal mast cells in vitro the proteolytic pattern was 
characterized by the appearance of two fragments. The molecular masses of the 
produced apoA-I fragments were identified only by SDS-PAGE. The fragments were, at 
the time, considered as being 26kDa and 24kDa of apparent molecular mass but it is 
likely that the latter is in fact the 22kDa fragment.  
In conclusion, systemic mast cell activation and the release of the mast cell proteases 
resulted in the proteolytic modification of native lipoproteins in mice. The protease 
most likely responsible for the observed HDL modification was the mMCP-4, present in 
CTMCs which are located in the connective tissue of many organs such as the 
peritoneum, skin and the heart  (Pejler et al. 2007). The mMCP-4 is the functional 
analog for human chymase  (Pejler et al. 2010). The proteolytic modifications were not 
only limited in the amount of HDL but the lipid compositions were also altered. Local 
mast cell activation by C48/80 in the rat heart ex vivo and in the peritoneal cavity of 
mice in vivo both led to the production of proteolyzed lipid-free apoA-I characterized in 
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both cases by the production of two fragments. These fragments were identified from 
the collected coronary effluent  as the apoA-I degradation products Phe229 and Tyr192 
previously reported for human chymase in vitro (Usami et al. 2013). Cardiac mast cell 
activation by moderate ischemia resulted in the production one apoA-I degradation 
product (Tyr192). This study reveals that mast cell chymase is able to degrade lipid-free 
apoA-I in different body compartments and HDL present in mouse serum after systemic 
mast cell activation. The substrates of mast cell chymase can thus vary from the largest 
spherical HDL particles to the lipid-free apoA-I.  
 
2.2. Proteolytically modified HDL and lipid-free apoA-I as cholesterol acceptors in vitro 
HDL has antiatherogenic properties and high level of serum HDL cholesterol is inversely 
related to the risk of cardiovascular disease  (Weissglas-Volkov and Pajukanta 2010) 
mainly due to the cholesterol efflux promoting abilities of HDL (Fielding and Fielding 
1995, Tall 2008). However drugs aiming to increase serum HDL levels alone do not 
reduce the risk of coronary heart disease events, coronary heart disease deaths, or 
total deaths (Briel et al. 2009). Similarly patients with hereditary low levels of serum 
HDL together with significant lipoprotein modifications (Franceschini et al. 1980) and 
patients with functional mutations on LCAT coding genes resulting in decreased HDL 
production (Calabresi et al. 2009) do not have increased risk for CVD. It is thus apparent 
that not only the serum HDL concentration but also the HDL composition is crucial for 
the efflux promoting ability of HDL. It has been reported that the ability of HDL to 
promote cholesterol efflux from macrophages was strongly and inversely associated 
with both subclinical atherosclerosis and obstructive coronary artery disease in humans 
(Khera et al. 2011). In the same study several HDL-associated variables, including levels 
of total phospholipids, apoA-I, apoA-II, and apoE, were each significantly associated 
with cholesterol efflux capacity and smoking alone attenuated the efflux capacity of 
HDL and was suggested to be related to apoA-I oxidation. Also it has been shown that 
mouse serum containing chymase treated preβ-HDL, apoA-II and apoE as well as HDL3 
all have decreased ability to promote cholesterol efflux from cholesterol loaded foam 
cells (Lee et al. 2002, Favari et al. 2004, Lee-Rueckert and Kovanen 2006). Therefore it 
was hypothesized that the ability of the in vivo degraded cholesterol acceptors 
described above would also have impaired ability to promote cholesterol efflux from 
macrophage foam cells in vitro.  
In the model of systemic mast cell activation, serum and intraperitoneal fluid were 
collected from wild type and mast cell deficient mice treated with C48/80 and the 
ability of serum and intraperitoneal fluid to promote macrophage cholesterol efflux 
was assessed.  Both serum and intraperitoneal fluid from wild type mice had reduced 
abilities to promote cholesterol efflux from macrophage foam cells after C48/80 
treatment compared to vehicle treated mice. Conversely, serum and intraperitoneal 
fluid from mast cell-deficient mice treated with C48/80 had no alteration in efflux 
promoting abilities compared to serum and intraperitoneal fluid collected from vehicle 
treated mice.  Together these results revealed that the loss of efflux promoting abilities 
was due to large-scale mast cell activation. This was the first time that it was shown 
that HDL proteolysis due to mast cell activation could occur in vivo. This in line with the 
previous reports describing that the antiatherosclerotic functions of HDL are not strictly 
related to the level HDL particles but, importantly, also on the preservation of HDL 
particle integrity  (von Eckardstein et al. 2001). The cholesterol transporters on 
macrophage foam cells responsible for the unidirectional efflux of intracellular 
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cholesterol are the ABCA1 and ABCG1. ABCG1 receptor depends on the interaction of 
mature spherical HDL particles whereas cholesterol efflux via ABCA1 requires direct or 
indirect apoA-I binding either as lipid-poor apoA-I or as small discoidal HDL  (Cuchel and 
Rader 2006). The interaction of these receptors with HDL particles or apoA-I depends 
on their availability and structural integrity. Although serum apoA-I level was reduced 
in the model of systemic mast cell activation it is not likely to be solely responsible for 
the massive reduction in cholesterol efflux capacity. Also the changes in HDL 
composition and importantly the alterations in the cholesterol/phospholipid ratio due 
to a stronger designated reduction in phospholipids in mast cell-modified HDL particles 
may account for the observed reduction for phospholipids are required for an effective 
cholesterol efflux (Zhao et al. 1996). 
In the model of local mast cell activation in the peritoneal cavity of mice a moderate 
degree of mast cell activation was induced by a lower dose of C48/80. As described 
above due to mast cell activation apoA-I was decayed in the peritoneal cavity. The 
efflux capacity of peritoneal fluid collected from apoA-I treated mice was compared 
after intraperitoneal injection of C48/80 or vehicle. Similarly to previous reports 
highlighting the importance of apoA-I in ABCA1 mediated cholesterol efflux  (Curtiss et 
al. 2006) it was demonstrated in this study that peritoneal fluid after injection of apoA-I 
alone was able to significantly promote cholesterol efflux compared to vehicle treated 
mice. Local peritoneal mast cell activation on the contrary was able to block such 
promotion. Small lipid-poor apoA-I particles are known to be susceptible to proteolytic 
modification (Lee et al. 2003) and this finding added to the previous result, showing 
that systemic mast cell activation was able to retard the ability of cholesterol acceptors 
present in mouse serum and intraperitoneal fluid to promote cellular cholesterol efflux. 
Treatment with C48/80 had dose dependency reflecting that more sufficient mast cell 
activation was more effective in suppressing the stimulatory effect of apoA-I to 
promote cholesterol efflux. Identical results were obtained from the performed in vitro 
studies. Human lipid-free apoA-I was incubated with increasing amounts of mouse 
chymase, starting with chymase activity roughly representing 10% of that present in 
the total population of peritoneal mast cells and exceeding 800%. Again there 
appeared to be a dose response in the efflux capacity of chymase treated apoA-I, the 
highest chymase activity representing the lowest efflux capacity. Of note the most 
drastic change was however seen already with the lowest chymase activity almost 
entirely blocking the efflux capacity of apoA-I.  
In summary, this study revealed that mast cell activation in vivo is able to produce 
dysfunctional HDL and apoA-I. Mast cell activation both systemically and locally 
resulted in blunted ability of cholesterol acceptors to promote cellular cholesterol 
efflux in vitro. The proteolytic modifications described in the above section were able 
to render the conformation of HDL and apoA-I in such a manner, that they were unable 
to interact with the ABC transporters. The efflux capacity of apoA-I after being perfused 
through rat heart after mast cell activation was not evaluated. By the analysis of 
cleavage sites on apoA-I It is plausible that similar reduction in efflux capacity would 
ensue.  These results confirmed that the previously described chymase dependent 
proteolytic modifications in vitro could indeed occur in vivo. These findings also gave 
support for the further studies examining the role of mast cell activation in the entire 
mRCT pathway. 
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2.3. Effect of mast cell activation on mRCT 
Efflux of cholesterol from foam cells is the first step in the mRCT process. However the 
efflux is only the initiation in the RCT process and the fate of the effluxed cholesterol in 
the HDL particles could have many outcomes. First, HDL in the interstitial space is taken 
up by endothelial cells on lymphatic vessels through the interaction of SR-BI receptor  
(Lim et al. 2013) and thus travels through the lymph to blood circulation. The 
cholesterol from HDL is taken up by the liver in receptor mediated pathway or as 
holoparticle together with HDL and from liver it is further secreted to bile as free 
cholesterol or as bile acids, both through receptor mediated pathways (Annema and 
Tietge 2012). Finally in the gut some of the cholesterol is reabsorbed and it has been 
shown that inhibition of cholesterol absorption from the gut significantly increases the 
overall RCT from peripheral tissues  (Sehayek and Hazen 2008, Silvennoinen et al. 
2012). Therefore, to verify the results obtained from the in vitro efflux studies, mRCT 
assay was adapted to study the entire pathway of cholesterol transportation from 
peripheral tissues to final excretion in feces in models of local mast cell activation. 
Systemic mast cell activation could not be used since it leads to anaphylactic shock and 
within 30 minutes and such short time period is not nearly long enough to study the 
multistep pathway of RCT. 
Effect of local mast cell activation in the peritoneal cavity was studied in a model 
described above. Mice received human lipid-free apoA-I to stimulate mRCT and C48/80 
was given to activate peritoneal mast cells. ApoA-I stimulated cholesterol efflux in vitro 
as described above and this same stimulatory effect translated to mRCT measured in 3 
hours as the transfer of [3H]cholesterol from J774 foam cells to intestinal content. In a 
mouse, apoA-I is rapidly associated with HDL particles when it enters the circulation 
and depending on the molecule size they are taken up by the liver (larger particles) or 
by the kidneys (smaller particles)  (Lee et al. 2004). The clearance of apoA-I and mast 
cell activation are rapid and thus the established mRCT model was shortened to 3 
hours. The preβ-HDL associated and lipid-free/poor apoA-I efficiently remove 
cholesterol from foam cells and it was plausible that in the 3 hour mRCT model the 
initial high dose of apoA-I offered sufficient amounts of active ligand to ABCA1 for 
cholesterol efflux. The apoA-I receiving cholesterol were transformed to HDL particles, 
sufficiently large in size to be removed by the liver, rather than by the kidneys, and thus 
the [3H]cholesterol was detected in the intestinal contents. Identically to the in vitro 
cholesterol efflux studies the activation of peritoneal mast cell was able to delete the 
stimulatory effect apoA-I on mRCT. When C48/80 was given to mast cell deficient mice 
no decline in the mRCT promoting ability of apoA-I was observed. This finding strongly 
indicates that the effect indeed was mast cell dependent. Both lipid-free/poor apoA-I 
and preβ-HDL particles are susceptible to proteolytic modifications namely to chymase 
dependent degradation (Lee-Rueckert et al. 2008) and it is likely that the reduction in 
mRCT in  C48/80 treated mice documented in this study was due to this apoA-I 
proteolytic modification. This hypothesis is authenticated by the sharp decay found in 
human apoA-I preβ-migrating species in peritoneal fluid of the C48/80 treated mice. 
Furthermore local peritoneal mast cell activation was unable to abolish the stimulatory 
effect of mRCT of the intraperitoneally injected cholesterol-free phospholipid small 
unilamellar vesicles (SUV). SUV induce aqueous diffusion of cholesterol from foam cells  
(Rodrigueza et al. 1997) and are not susceptible to proteolysis. Mast cell activation did 
not, however, affect the basal rate of mRCT (without apoA-I treatment) in 3 hours. As 
described above mast cell activation increases vascular permeability. Thus, even if mast 
cell chymase was able to degrade the local small discoidal preβ-HDL particles, naturally 
occurring in interstitial fluid (Randolph and Miller 2014), the increased influx of both 
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the preβ-HDL particles and the larger α-HDL particles from the plasma compartment 
would probably restore the mRCT back to the basal level. Granule phagocytosis by the 
local peritoneal macrophages and by the locally injected J774 macrophages could 
likewise play a part in diminishing the granule-bound chymase effect (Baggiolini et al. 
1982). Unlike the apoA-I treatment which rapidly and sharply increases mRCT and also 
is promptly inactivated by chymase the 3 hour mRCT  is a short time to study the full 
extent of mast cell activation on the naturally occurring cholesterol acceptors since the 
appearance of the newly synthesized mast cell mediators also affecting vascular 
permeability could not be accounted for in only 3 hours (Mekori and Metcalfe 2000).   
To further study the relevance of mast cell activation in a more “atherosclerotic-like” 
setting, mRCT originating from foam cells injected to the skin was evaluated. Skin and 
arterial intima have been suggested to share some similarities in their cholesterol 
balance and metabolism. Genetic deletion of apoA-I in humans results in the formation 
of skin xanthomas, depositions of cholesterol and lipids in foam cells, resembling those 
found in atherosclerotic lesions (Matsunaga et al. 1991, Lackner et al. 1993). The 
formation of skin xanthomas and atherosclerotic lesions share similarities and can be 
found hand-in-hand in animal models (Ishibashi et al. 1994, Zhang et al. 2006) and in 
humans carotid media intima thickness correlates with the cholesterol accumulation to 
skin (Tzou et al. 2005). Thus skin, rich in resident mast cells, comes to be an ideal place 
to study mast cells and mRCT.  
Mast cells in the skin were activated by C48/80 similarly to the described experiments. 
After mast cell activation cholesterol laden J774 cells were injected to the same skin 
site and mRCT was evaluated by collecting the fecal tracer after 48h. Interestingly, in 
contrast to the described experiments in which mast cell activation retarded the apoA-I 
mediated increase in mRCT and the in vitro cholesterol efflux from foam cells to 
plasma, mast cell activation in skin was able to promote mRCT. The stimulatory effect 
was related to increased influx of HDL from plasma compartment to skin, similarly as 
previously reported for LDL in a similar setting (Ma and Kovanen 1997). To further 
study the underlying mechanism, three mast cell mediators, all capable of increasing 
vascular permeability, were studied individually in their abilities to promote mRCT. 
Each histamine, serotonin, and bradykinin alone were able to promote mRCT and the 
fecal recovery of [3H]cholesterol. Histamine effect was blocked by an H1R antagonist 
rather than an H2R antagonist similar to a pervious report describing an increased 
passage of LDL through monolayers of human arterial endothelial cells due to a 
histamine effect blocked by an H1R antagonist  (Langeler et al. 1989). Thus it appeared 
evident that a mere increase in vascular permeability at the site of foam cells was 
sufficient to promote mRCT in mice with naturally occurring high serum HDL levels 
(Camus et al. 1983). This was further demonstrated by an increased influx of HDL to the 
skin after intra venous injection of HDL and sub cutaneous injection of histamine, 
serotonin or bradykinin. These inflammatory mediators were responsible for increased 
flux of HDL to skin and thus promoting mRCT from skin to feces. Importantly histamine 
injection to apoA-I deficient mice was unable to promote mRCT. ApoA-I knockout mice 
are deprived of the major cholesterol acceptors and thus despite of the induction of 
increased vascular permeability by histamine these mice had only basal mRCT levels.  
Supplementation of HDL by venous injection of isolated mouse HDL was able to restore 
the ability of histamine to promote mRCT. These findings further proved that the HDL 
and its increased flux to skin due to increased vascular permeability were responsible 
for the promotion of mRCT. Interestingly, in LDLr-KO mice which have naturally 
occurring high levels of serum apoB-containing lipoprotein, histamine treatment failed 
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to promote mRCT. Furthermore, the basal mRCT rate in these mice appeared to be 
increased in the untreated LDLr-KO mice relative to the untreated wild-type mice. This 
increase could relate to enhanced vascular permeability described in association with 
hypercholesterolemia in mice (Phinikaridou et al. 2013). It is thus likely that in a setting 
in which the endothelium is already leaky, histamine would not have such a 
pronounced additional effect on vascular permeability.  
These two apparently opposite results on the effect of mast cell activation on 
cholesterol homeostasis can be explained at least by the nature of the cholesterol 
acceptors, the extent of mast cell activation and by the balance between the vasoactive 
and proteolytic effects present in each experimental setup. In the model of mRCT 
originating from the peritoneal cavity, the mice were transitorily supplied by a large 
single dose of lipid-free apoA-I, approximately representing 10-fold more than that 
found in the peritoneal cavity of a normal mouse. These lipid-free particles are highly 
susceptible to proteolytic modification but also extremely efficient in promoting 
cholesterol efflux via ABCA1 mediated pathway. Thus apoA-I clearly increased the 
mRCT and this effect was blocked by mast cell activation. In the skin mRCT model on 
the other hand, the mice were not supplied by exogenous cholesterol acceptors. mRCT 
was stimulated by the endogenous HDL particles originating from plasma compartment 
of the mouse. The interstitial fluid under normal conditions is rich in small discoidal 
HDL particles but the serum in contrast, has only up to 5% of the small preβ-migrating 
HDL particles and the rest is of the more mature spherical α-HDL form (Ishida et al. 
1987). When vascular permeability is increased this same ratio of HDL particles 
infiltrates the interstitium. Even if this 5% of the HDL particles would be degraded the 
remaining 95% will not be collectively blunted in their ability to promote macrophage 
cholesterol efflux. Larger HDL2 and HDL3 particles efficiently induce cholesterol efflux 
actively through ABCG1 transporter and passively through SR-BI and also to some 
extent by aqueous diffusion (Rothblat and Phillips 2010). These mechanisms likely 
override the blunted ABCA1 mediated pathway. This is line with the finding that mast 
cell activation was unable to effect the 3 hour mRCT originating from the peritoneal 
cavity. Possibly in the 3 hours the full mast cell effect was not yet measurable. Apart 
from histamine, bradykinin and serotonin, several newly synthesized mast cell 
mediators and longer acting mediators such as tryptase and also chymase are involved 
in increasing vascular permeability (Kunder et al. 2011). Some of the granules 
remaining in the tissue might be expelled by phagocytosis but the vascular effect of 
mast cell activation probably remains effective for a longer time. Thus in the 3 hours 
the effect is evidently not seen but in the longer time period of 48 hours the effect is 
prominent. In the model of systemic mast cell activation also the amount of the larger 
α-HDL particles was reduced. This is probably due to maximal mast cell activation 
where nearly all mast cells are activated and get to close contact with the several 
plasma HDL particles. It has been shown that both chymase and tryptase are able to 
degrade HDL3 in vitro  (Lee-Rueckert and Kovanen 2006). Such massive reduction in 
cholesterol acceptors would likely be enough to affect the mRCT but induction of 
anaphylaxis is a terminal procedure and does not allow explorations of a longer 
duration.  
In summary local mast cell activation has the ability to influence mRCT. The net effect 
of mast cell activation on mRCT depends on the cholesterol acceptors present in the 
vicinity of macrophage foam cells and apparently on the degree and time-frame of 
mast cell activation. Lipid-free apoA-I mediated increase in mRCT is blunted by mast 
cell activation while the bulk of plasma HDL remains functional and promotes mRCT. It 
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would be an interesting future study to explore, whether a longer, sustained mast cell 
activation would have a similar effect on mRCT or would the prolonged mast cell 
dependent effect on the vascular endothelial cells be resisted over time and overridden 
by the proteolytic effect of mast cell proteases acting on the local discoidal preβ-HDL 
particles that enrich the interstitial fluids. 
 
2.4. General discussion and future aspects 
In the present study, it was shown for the first time that mast cell activation can lead to 
the production of protease-modified HDL in vivo. It is well established that the 
subpopulation and the functionality of HDL particles determine the efflux capacity of 
these particles (Rothblat and Phillips 2010). ABCA1 and ABCG1 are the only 
unidirectional cholesterol transporters leading to net removal of macrophage 
cholesterol. The importance of the ABCA1 mediated pathway is highlighted by a rare 
genetic loss-of-function mutation in the gene encoding the ABCA1 in humans in Tangier 
disease, characterized by severe HDL deficiency and cholesterol accumulation in 
peripheral tissue macrophages (Rader et al. 2009). When apoA-I is degraded the ABCA1 
mediated pathway is blunted as shown in this study. Importantly even if ABCG1 could 
compensate for the loss of the ABCA1 mediated pathway it has been shown that 
ABCA1 and ABCG1 function synergistically. While ABCG1 is unable to promote 
cholesterol efflux to apoA-I, cholesterol efflux to apoA-I through ABCA1 results in the 
formation of nascent or preβ-HDL and further to αHDL which may in turn serve as 
substrates for ABCG1-mediated cholesterol export  (Gelissen et al. 2006). This pathway 
is extremely relevant in extravascular tissues where most apoA-I is present.  
In animal models the rate of RCT has been shown to be a better predictor of 
atherosclerosis development than serum HDL cholesterol levels  (Rader et al. 2009). 
Generally speaking increased RCT predicts decreased atherosclerosis development. In 
this study it was for the first time demonstrated that the modifications in HDL structure 
resulting from chymase proteolysis can lead to decreased mRCT. This study 
demonstrates in three models the formation of proteolyzed apoA-I and HDL particles. It 
was shown that cellular cholesterol efflux in vitro was decreased when such 
proteolyzed particles were used as cholesterol acceptors. Proteolysis of apoA-I 
occurred rapidly within in a minute, in one infusion through the heart. Drugs to 
increase serum HDL-cholesterol levels have been vigorously tested, but despite of the 
increase in serum HDL levels, they have not been able to affect serum LDL levels or the 
progression of atherosclerosis (Briel et al. 2009). This could be related to the formation 
of dysfunctional apoA-I under atherogenic conditions in which mast cell number and 
the level of mast cell activation are increased  (Kaartinen et al. 1994B, Kovanen et al. 
1995). Cardiac mast cells under atherosclerotic conditions can be activated by oxidized 
LDL, found in atherosclerotic plaques (Lappalainen et al. 2011), pro-atherogenic 
bacteria Chlamydia pneumoniae and Aggregatibacter actinomycetemcomitans  
(Oksaharju et al. 2009), stress (Pang et al. 1998, Huang et al. 2002) and ischemia 
(Frangogiannis et al. 1998). Thus despite of the increase in serum HDL this does not 
predict the efflux or RCT promoting abilities of the HDL present in serum. Activated 
mast cells in the heart could proteolyze at least the apoA-I present in the intimal fluid. 
It would be an interesting trial to study the fate of apoA-I in cholesterol efflux and RCT 
in animals with activated cardiac mast cells. This could be carried out by exposing mice 
to psychological stress. It has been reported however that psychological stress in mice 
without exogenous promoters for RCT have increased mRCT through corticosterone-
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dependent mechanism involving decreased cholesterol absorption from the gut 
(Silvennoinen et al. 2012). The ex vivo activation of cardiac mast cells and the ability of 
different cholesterol acceptors to promote cholesterol efflux after being perfused 
through the heart could also be studied. Additional studies in atherosclerotic animal 
models (apoE-/- or LDLR -/-) are required to elucidate whether activation of mast cells in 
the atherosclerotic arterial wall or in the skin would reduce the macrophage 
cholesterol efflux promoted by cholesterol acceptors present in the interstitial fluid and 
so attenuate the initiation of the mRCT.  
In the present work it was demonstrated that apoA-I supplementation into the 
peritoneal cavity was able to promote mRCT. This in in line with previous studies in 
which apoA-I overexpression resulted in increased RCT and regression of 
atherosclerosis  (Escola-Gil et al. 2009). Mast cell activation in the peritoneal cavity was 
able to fully block such promotion. Also in systemic mast cell activation, the lipoprotein 
profile in mice was altered and their cholesterol efflux abilities were markedly reduced. 
On the contrary mast cell activation in the skin without exogenous supplementation of 
apoA-I was able to increase mRCT. This was due to the increased vascular permeability 
and the increased influx of cholesterol acceptors to the site of foam cells. Mast cells 
release vasoactive compounds together with the serine proteases, among others. 
Histamine is able to induce vascular permeability leading to leakage of fluid and plasma 
components to interstitial fluid but it has been recently shown that histamine also 
decreases the pumping action and disrupts endothelial barrier function in lymphatic 
vessels  (Breslin 2011, Nizamutdinova et al. 2014). In the present study histamine and 
other mast cell mediators were able to promote mRCT even with the negative effect of 
histamine on lymphatic vasculature possibly leading to retention of interstitial fluid to 
the site of mast cell activation. Thus the interplay of the inward and outward flow of 
HDL on RCT rate deserves further investigation in animal models with decreased 
lymphatic function.  
Finally, the net effect on RCT and atherosclerosis development depends on the 
availability and integrity of lipoproteins interacting with the macrophage foam cells. In 
the model of local cutaneous mast cell activation the available serum lipoproteins in 
normal mice were mostly HDL particles since more than 70% of total cholesterol is HDL 
cholesterol in wild type mice (Camus et al. 1983). In the present study the conducive 
effect of increased permeability on mRCT was blunted in mice with genetic depletion of 
apoA-I since the active cholesterol acceptors were not available.  On contrary in 
atherosclerosis prone apoE-/- mice with increased serum LDL levels, increased 
permeability through histamine H1R leads to the progression of atherosclerotic lesions  
(Rozenberg et al. 2010). Accordingly it was demonstrated that in LDLr-KO mice 
histamine treatment did not increase mRCT but surprisingly these mice had increased 
rate of basal mRCT. This finding agrees to the notion that mRCT is increased in mice fed 
with high cholesterol diet (Escola-Gil et al. 2011). In both of these cases the efflux of 
macrophage cholesterol to apoB-containing lipoproteins could predominate when their 
concentration exceeds that of HDL (Wang et al. 2004).  In humans approximately 70% 
of serum cholesterol is LDL cholesterol and the rest 20-30% is HDL cholesterol (Lehto et 
al. 1992). Thus the likelihood for the progression of the atherosclerotic lesions would 
be greater than the regression especially in patients with dyslipidemia. On the other 
hand infusion of apoA-I has been shown to reduce plaque size  (Chiesa et al. 2002). 
Such infusion could be accompanied by local increase in vascular permeability and this 
could lead to accelerated RCT resulting in regression of atherosclerosis. Local mast cell 
activation could be a means to induce increase in vascular permeability but mast cell 
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chymase could at the same time proteolyze the infused apoA-I. These observations 
reflect opposite actions of mast cell granule mediators and add support to the 
therapeutic concept of targeting mast cell chymase, when developing specific inhibitors 
of mast cell actions, shown also to prevent cardiac fibrosis and to improve diastolic 
dysfunction (Matsumoto et al. 2003).  Thus further studies on individual mast cell 
mediators and their effects on RCT in mouse models together with treatments 
increasing serum HDL or apoA-I levels would further elucidate the mast cell dependent 
progression of atherosclerosis. Meanwhile the ratio between the proatherogenic LDL 
and the anti-atherogenic HDL in serum abides as the main strategy when aiming to 
prevent the foam cell formation or trying to accelerate their regression.   
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CONCLUSIONS  
 
The present study investigated the effects of mast cell activation in relation to HDL and 
lipid-free apoA-I in cell culture environments, isolated heart model, and in 
experimental animal models focusing on mRCT. Based on the publications I-IV and the 
discussion above the following conclusions, summarized in Figures 9 and 10, are drawn:  
 
1. Mast cells activation leads to quantitative and qualitative changes in HDL 
structure 
During systemic mast cell activation HDL subpopulations were proteolytically 
modified. Both mature α-HDL and preβ-HDL populations were reduced in 
mouse serum. Also serum apoA-I, apoA-IV and apoE were reduced after 
systemic mast cell activation. Similar changes in HDL and apoA-I structure were 
also documented in vitro.  
 
2. Mast cell activation leads to the formation of C-terminally truncated apoA-I   
Lipid-free apoA-I, infused through rat heart after activation of cardiac mast 
cells by C48/80, is C-terminally truncated at sites Phe229 and Tyr192 leading to 
the formation of two apoA-I fragments with molecular masses of 26.458Da and 
22.395Da, respectively. Cardiac mast cell activation by moderate cardiac 
ischemia results in apoA-I truncation at Tyr192 (22.395Da). Phe229 and Tyr192 
were also produced by human chymase in vitro with an additional 25.964Da 
fragment cleaved at Phe225 while rat chymase produces only one fragment 
(Tyr192, 22.395Da).  
 
3. Chymase dependent HDL proteolysis results in reduced cholesterol efflux 
capacity  
Serum and intraperitoneal fluid collected from mice subjected to systemic 
mast cell activation had reduced cholesterol efflux capacities from macrophage 
foam cells. Similarly peritoneal fluid collected from mice treated with human 
lipid-free apoA-I after local peritoneal mast cell activation had reduced efflux 
capacity. A dose dependent reduction in apoA-I efflux capacity was observed 
after more extensive mast cell activation in vivo as well as after incubating 
apoA-I with increasing chymase activities in vitro. 
 
4. Local peritoneal mast cell activation is able to block apoA-I dependent 
promotion of mRCT 
Supplementation of apoA-I to the peritoneal cavities of mice was able to 
promote mRCT in the 3 hour experiment. Mast cell activation by C48/80 was 
able to fully block such promotion. Similarly apoA-I pretreated with mouse 
chymase was unable to promote mRCT. Mast cell activation was unable to 
block the mRCT promoted by cholesterol-free phospholipid vesicles. Treatment 
that led to mast cell activation and reduction in mRCT in mast cell competent 
mice was unable to affect mRCT in mast cell deficient mice. Mast cell activation 
without exogenous apoA-I did not reduce or affect the overall mRCT. 
   
71 
 
 
 
 
 
Figure 9. Mast cell activation results in the formation of proteolytically modified HDL and apoA-I 
leading reduced cholesterol efflux and mRCT 
Local mast cell activation leads to the release of intracellular granules containing chymase. Chymase is 
able to proteolyze lipid-free human apoA-I leading to the formation of C-terminally truncated apoA-I. 
Rat cardiac mast cell chymase is able to cleave apoA-I either at Phe
229 
and Tyr
192 
leading to the 
formation of two apoA-I fragments 26.458Da and 22.395Da of molecular mass or only at Tyr192 
depending on the mast cell stimulus. Proteolytically modified apoA-I has reduced cholesterol efflux 
capacity from macrophage foam cells in vitro and this also translates to mRCT in vivo. Proteolysis of 
apoA-I can also lead to decreased production of preβ-HDL and α-HDL leading to reduced cholesterol 
efflux to these particles as well. Systemic mast cell activation leads to reduction in both of preβ-HDL 
and α-HDL and HDL structural components apoA-I, apoA-IV and apoE in serum and reduction in apoA-I 
in peritoneal fluid. Such serum and peritoneal fluid have reduced cholesterol efflux capacities.   
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5. Increased vascular permeability due to mast cell activation leads to influx of 
HDL to the skin and consequently to increase in mRCT in normolipemic mice  
Mast cell activation and three mast cell inflammatory mediators, histamine, 
serotonin and bradykinin increased vascular permeability and led to the influx 
of plasma HDL to skin. This influx of HDL was able to promote RCT from skin to 
feces. Histamine effect was blocked by H1- but not by H2-receptor antagonist 
alone and administration of the two antagonists together presented an 
additive inhibitory effect. Increased vascular permeability in apoA-I deficient 
mice was unable to promote RCT.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. Increased vascular permeability leads to influx of plasma HDL and promotion of 
mRCT from skin 
Mast cell activation by C48/80 and sub cutaneous injections of histamine, serotonin or 
bradykinin leads to influx of plasma HDL to skin. This increase in HDL in the skin is able to 
promote mRCT conceivably by increasing the unidirectional efflux of cholesterol from 
macrophage foam cells via ABCA1 and ABCG1 transporters. Cholesterol is removed from the 
skin via lymphatics to blood circulation and liver and finally through bile to feces. Increased 
vascular permeability in apoA-I deficient mice is unable to promote mRCT due to the lack of 
the naturally occurring active cholesterol acceptors. When HDL is injected intravenously to 
the apoA-I deficient mice the ability of increased permeability to promote RCT is recovered.   
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